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grateful to my second assistant supervisor, Professor Karina Aase, for sharing her 
insights and providing guidance in qualitative research designs. It has indeed been an 
interesting and exciting journey. I would also like to thank Karina for valuable 
feedback, providing me with new insights.  
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College, London, taught me so much about antimicrobial stewardship and behaviour 
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Increasing antimicrobial resistance rates are recognised as a global public health 
threat and many efforts are being undertaken to curb this development. One important 
measure is to optimise the use of antibiotics and microbiology testing, which is of 
significance to target antibiotic therapy. The aim of this thesis was to gain new 
knowledge on what factors influence antibiotic prescribing practices in Norwegian 
hospitals, highlighting the use of microbiology tests. This knowledge will be applied 
to outline targeted interventions for optimised antibiotic prescribing in Norwegian 
hospitals. 
The aim was addressed in three separate, but interconnected studies. First, factors 
influencing antibiotic prescribing practices among hospital physicians were studied, 
using an explorative qualitative study design and semi-structured interview 
methodology. The same design and methodology was applied in study 2, to 
investigate communication barriers between microbiology laboratories and clinical 
units and how they can be addressed. In study 3, a multi-centre cohort study design 
was used to study microbiology test ordering practices in hospitals and how 
microbiology test results are used to inform antibiotic decision-making. 
Main findings were that colleagues, in particular ID physicians, the national guideline 
on antibiotics, microbiology test results, training, patient assessment and informal 
leaders influenced antibiotic prescribing practices in hospitals. The availability of the 
national antibiotic guideline was impaired, training was mainly informal, the hospital 
leaders were absent in promoting antibiotic prescribing policies and delayed 
availability of microbiology test results was perceived as a barrier for targeting 
antibiotic treatment.  
The main barrier to communication between clinical units and the microbiology 
laboratories was disruption related to logistics of specimen, information on request 
forms, verbal reporting of test results and information transfer between poorly 
integrated IT systems. Communication was also challenged by lack of insight into 
each other’s area of expertise and limited provision of laboratory services.  
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Mean compliance with microbiology testing recommendations in the antibiotic 
guideline was 89%, but a substantial proportion of additional testing was performed 
beyond the recommendations. Altogether, 298/606 (49%) of patients with lower 
respiratory tract infections had urine cultures and 42/194 (22%) of patients with 
urinary tract infections had respiratory tests. Some microbiology tests had poor 
performance characteristics and only half of the applicable test results were used for 
therapy guidance. As a result, only 9% (63/672) of test results informed antibiotic 
decision-making. 
These findings highlight the importance to perform studies on antibiotic prescribing 
practices and use of microbiology tests in specified contexts to identify targeted 
interventions for optimisation of antibiotic use in each context. 
A national Antimicrobial Stewardship (AMS) programme may be a suitable 
organisational framework to implement these interventions. This thesis showed that 
ID physicians have a crucial role to play in hospital AMS teams as they were trusted 
colleagues in infection management. It also identified that hospital AMS programmes 
should include interventions to improve the use of microbiology tests through a 
review of all the steps of the diagnostic pathway. Microbiologists can facilitate this 
review and should preferably be members of the AMS teams. Furthermore, the AMS 
programmes should establish educational programmes on infection management and 
microbiology for clinical- and microbiology laboratory staff.  
Finally, the thesis identified a need for interventions at the national level. It must be 
ensured that the national antibiotic guideline remains relevant by securing its 
availability on several platforms and by regular updates. Hospital leaders should be 
made accountable for implementing AMS programmes locally and responsible for 
reaching national targets to optimise antibiotic use in Norwegian hospitals. 
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1. Introduction 
Antimicrobial resistance (AMR) rates are increasing worldwide, including in 
Norway, though resistance rates, AMR attributable morbidity and mortality is low 
compared to other countries (1; 2). Something changed in Norway in 2015, as a 
patient died at Haukeland University Hospital from sepsis caused by multidrug 
resistant bacteria, for which there were no antibiotic treatment options (3). The 
patient, a resident of Norway, had undergone a severe burn injury in Pakistan and 
been colonised by multidrug resistant bacteria during her stay in a Pakistani hospital, 
before being transferred to Haukeland University Hospital. This was a brutal 
reminder of the potentially fatal consequences of AMR and its global public health 
implications. An increasing number of systematic reviews and evidence based reports 
on AMR reflect the urgency of the problem, it´s potential consequences and a variety 
of interventions to contain AMR, upon which this introduction is based. 
1.1 Antimicrobial resistance 
1.1.1 What is antimicrobial resistance? 
AMR is defined as “the bacteria, viruses, parasites and fungi´s ability to resist the 
action of an antimicrobial agent” (4). Antibiotic resistance is a more narrow term, 
referring only to bacteria’s ability to resist the effects of antibiotics (5). Despite this 
distinction, and the fact that antibiotic resistance currently constitutes a greater public 
health challenge than resistance to viruses, parasites and fungi, the terms AMR and 
antibiotic resistance are often used interchangeably. This thesis will apply “AMR” as 
this is a well-established international term. Since the main issue of this thesis is 
about antibiotic prescribing and not antimicrobial prescribing altogether, antibiotic 
will be used in the context of prescribing and use of these agents. 
 AMR evolves naturally, through a Darwinian selection process by genetic mutation 
and recombination, and resistance genes may spread horizontally between species (6). 
The evolution of AMR accelerates by exposure to antibacterial compounds in the 
human- and animal sector and to other contaminants, such as heavy metals in the 
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environment. This exerts a “selection pressure”, where the most resistant microbes 
survive and duplicate (7). The literature indicates that the global increase in AMR 
correlates with a significant increase in antibiotic consumption in humans and in the 
food supply chain (6).   
All bacteria can express resistance, but the most common of relevance for human 
health are Staphylococus aureus resistant to Methicillin and related beta lactam 
agents (MRSA), Enterococci resistant to Vancomycin (VRE) and Enterobacteriaceae 
producing extended-spectrum beta-lactamases (ESBLs), which destroy the effect of 
different beta lactam antibiotics on these bacteria (4). In high income countries 
(HICs), infections caused by resistant gram-positive bacteria in humans (i.e. MRSA 
and VRE) are treated by a range of alternative antibiotics. For resistant gram-negative 
bacteria there are few alternative treatment options. In fact, no novel antibiotic class 
with activity against gram negative bacteria has been discovered since 1962, 
highlighting an urgent need for the development of new treatments (8). Novel 
treatment options are needed for several bacteria, but from a global public health 
point of view the following are identified as most critical:  carbapenem-resistant 
Acinetobacter baumannii and Pseudomonas aeruginosa, and carbapenem- and third-
generation cephalosporin-resistant Enterobacteriaceae, and Mycobacterium 
tuberculosis (9).  
1.1.2 How is antimicrobial resistance distributed? 
The environment, human- and animal sector are all sources of AMR (6). The 
different sectors´ contribution to development of AMR and the interplay between 
them is not fully understood (7). Within the human sector, there is also a knowledge 
gap on the dynamics and relative contribution to development of AMR from the 
community (i.e. outside of hospitals) versus the hospitals (10). The vast majority of 
antibiotics are prescribed in the community, but historically AMR has mainly been 
considered as a hospital challenge (11). A hospital is a perfect environment for 
selection and spread of AMR. The many patients being treated with antibiotics 
provide a selective pressure on bacteria, selecting the most resistant ones. 
Furthermore, the proximity of severely ill, susceptible patients facilitates their spread 
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in crowded hospital environments (11). The consequences of the emergence and 
spread of resistant bacteria in hospitals are significant, as many hospital patients are 
vulnerable to infections (8).  
Geographically, AMR rates vary substantially (12). Unfortunately, there is a lack of 
AMR surveillance, especially in low and middle income countries (LMICs) (1). In 
some countries, the only available figures are from research studies, which report 
variable, but often high rates of AMR. For instance, publications from Kenya and 
Pakistan report that 87% and 94% of E coli are resistant to third-generation 
cephalosporins, respectively (1; 13; 14). In Europe, AMR rates also vary, by bacterial 
species and geographical region. There is a north - south and a west - east gradient, 
with lower resistance rates in the countries in the north and west. For instance in 
2016, the resistance rates in E coli and Klebsiella pneumoniae were in the higher end 
in Bulgaria and Romania, and in the lower end in Finland and Norway (15). 
 
1.1.3  What are the consequences of antimicrobial resistance? 
Higher resistance rates in bacteria are associated with higher morbidity, prolonged 
hospital stays and increased mortality, in part due to delayed recognition of resistant 
causative pathogens, but also due to reduced treatment options (16). The 
consequences are especially evident in LMICs where costly diagnostics and “last-
resort” medicines needed to treat infections with resistant bacteria may be unavailable 
and/or unaffordable (17). Increasingly resistant bacteria are a threat to patients with 
common infections such as pneumonia and sepsis, but even more so to 
immunocompromised patients undergoing organ transplantation or chemotherapy, 
intensive care patients or the pre-term infants. 
The lack of AMR surveillance data as well as the complexity of the issue, 
complicates the calculation of the global burden of AMR (6). Models of the burden of 
AMR related deaths suggest that AMR was attributable to about 33 000 deaths in 
Europe in 2015 (2). O´Neill et al. estimated that by 2050, 10 million deaths and 
increased expenses of 100 trillion USD per year would be attributable to AMR (18). 
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However, the methods used by O´Neill et al. for these calculations have been 
criticised (19). 
 
1.1.4 How to contain antimicrobial resistance? 
AMR is a global public health threat in need of a coordinated international response. 
In 2015, the WHO published a global action plan on AMR (17). Many countries 
followed suit and developed national action plans on AMR, including Norway (20; 
21). The global action plan outlines measures needed in the human, animal and 
environmental sector to mitigate further development and spread of AMR. The scope 
of this thesis is limited to interventions in the human sector, focusing on hospitals. 
Obviously, there is a need for novel therapeutic discoveries. It has proven challenging 
to develop new therapeutic agents, especially against gram negative bacteria. There is 
also little commercial impetus for the pharmaceutical industry to conduct research 
within this field, as the use of new medicines will be restricted in order to delay the 
emergence of resistance and prolong their lifespan. New financial concepts and 
incentives to fund basic research and clinical trials are increasingly being put in place, 
yet more is needed to overcome the drought of bringing new antibacterial 
therapeutics to the market (22). 
There is also an urgency to develop new, affordable diagnostic tools to reduce 
unnecessary use of antibiotics (17). Specifically, there is a need for affordable 
diagnostics assisting in the identification of patients with viral infections and not in 
need of antibiotics, as well as rapid diagnostics to identify causative bacterial 
pathogens and their antibiotic susceptibility, to target therapy (18). The role of 
diagnostics in stemming AMR will be elaborated below. The scope of this thesis is 




A better overview of the distribution of AMR in humans, animals and the 
environment is needed to develop targeted interventions against AMR. The WHO has 
developed manuals and systems to inform the development of surveillance 
programmes in humans (23). However, financial support and local capacity building 
are challenging for the establishment of AMR surveillance programmes in many 
LMICs (24).  
Infection prevention and control measures can limit the spread of resistant bacteria, 
e.g. by adequate hand hygiene, and reduce the number of infections in need of 
antibiotic treatment. Compliance with these measures is reported to be substandard 
globally, and it is necessary to strengthen the infection prevention and control 
measures (25; 26). A further preventive measure is to improve vaccination coverage 
and development of new vaccines, as their effectiveness in reducing the number of 
infectious diseases and AMR is well documented (27). 
Finally, there is a substantial number of reports showing an association between 
exposure of antibiotics and the emergence of AMR (28-30). Antibiotics should 
therefore be reserved to patients in need of them. However, there is clear evidence of 
overuse and misuse of antibiotics; up to 50% of all antibiotics prescribed are 
considered inappropriate, indicating a substantial potential for improvement (6). 
Measures for optimisation of antibiotic prescribing practices are to be elaborated 
below. 
1.2 Antimicrobial stewardship  
In 1996, the two American professors, Mc Gowan and Gerding, first used the term 
“Antimicrobial stewardship” (AMS), highlighting the uniqueness of antibiotics and 
the necessity to contain them as precious, limited resources for human medicine (31). 
Inspired by the church`s gospel of the “good stewards”, they advocated appropriate 
use as well as avoidance of unnecessary use of antibiotics. The concept 
“Antimicrobial stewardship” was then adapted in Europe in 1998 before it spread 
globally and became the collective term for appropriate use of antibiotics (32). AMS 
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were initially a hospital initiative, but are increasingly being implemented also in 
primary care and in the animal sector (31). 
1.2.1 Definition of antimicrobial stewardship 
The definition of AMS has evolved throughout the years, yet it has always balanced 
the individual patient’s immediate need for efficient antibiotic treatment and society´s 
long term need for sustained efficacy of these medicines (31). A frequently cited 
definition is the one developed by the Infectious Diseases Society of America and the 
Society for Healthcare Epidemiology of America in 2007, and updated in 2012:  
“AMS refers to coordinated interventions designed to improve and measure the 
appropriate use of antimicrobial agents by promoting the selection of the optimal 
antimicrobial drug regimen including dosing, duration of therapy and route of 
administration” (31; 33; 34). In other words, AMS interventions aim to systematically 
optimise and evaluate all aspects of antibiotic therapies to today´s patients, but at the 
same time consider the needs of future patients. 
In a more recent publication by the European Society of Clinical Microbiology and 
Infectious Diseases Study Group for Antimicrobial Stewardship, AMS is defined as 
“a coherent set of actions designed to use antimicrobials responsibly” (31). This 
definition highlights a system approach with less focus on prescribers, and is the 
definition applied in this thesis.  
1.2.2 Core elements of antimicrobial stewardship programmes 
The Infectious Diseases Society of America, the American Centers for Disease 
Control and Prevention and global experts have listed a set of core elements to guide 
establishment of AMS programmes (33; 35; 36). Although the lists are not identical, 
there is quite an overlap between them.  
Senior leadership commitment is considered essential for an AMS programme to be 
prioritised and funded, both at the national and the facility level. More specifically, 
leadership commitment is necessary to facilitate legitimacy for the programme as 
well as accountability and participation from hospital directors, clinical staff and units 
such as the laboratories. Finally, leadership commitment facilitates a formal structure 
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and a strategy that clearly defines organisation, roles and responsibilities, which are 
essential to the success of AMS programmes (36). 
It is recommended that the AMS programme has an interprofessional, coordinating 
committee or team with an appointed leader. Infectious disease (ID) physicians and 
pharmacists are considered mandatory AMS team members in the 2007 Infectious 
Diseases Society of America AMS guidelines. Several other professions are also 
considered relevant team members, including nurses, clinical microbiologists, 
infection prevention and control professionals, information technology specialists and 
clinical staff (33). Recent publications acknowledge that not all health care facilities 
have all kinds of health professionals, but emphasise that certain competencies and 
skills should be made available for an AMS programme, e.g. expertise in infection 
management and drugs (35; 36). 
Antibiotic treatment guidelines are considered a cornerstone in AMS programmes 
(33). They provide recommendations to prescribers on antibacterial agent, dose, route 
and duration for common infections such as pneumonia, urinary tract infection (UTI) 
intra-abdominal infection, skin and soft tissue infection (SSTI) and surgical 
prophylaxis.  Treatment guidelines are to be based on international or national 
evidence and on local antibiotic susceptibility data, when available. 
It is also considered essential for an AMS programme to set targets, to monitor 
changes and to evaluate implemented AMS interventions by tracking and reporting 
antibiotic use and outcomes (35). Regular reporting on both process and outcome 
measures are recommended (33; 35; 36). Audits and point prevalence surveys can be 
used to evaluate compliance to treatment guidelines and can be applied to assess 
whether the programme is implemented as intended. This would be considered a 
process measure (37). Outcome measures evaluate whether the programme has the 
desired effect, e.g. by tracking antibiotic consumption rates or long-term rates of 
antimicrobial resistant bacteria. Reporting on costs, mortality rates or length of stay 
could favourably be performed, but has so far not been a priority in AMS 
programmes (38). 
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1.2.3 Interventions to improve antibiotic prescribing practices 
Interventions to improve antibiotic prescribing practices are divided into persuasive, 
restrictive and environmental restructuring (39; 40). The different interventions and 









Using communication to induce 
positive or negative feelings or to 
stimulate action  
 
(41; 42) 
Restrictive Using rules to reduce the opportunity 
to engage in the (undesired) target 
behaviour or increase the (desired) 
target behaviour by reducing the 





Promoting target behaviour by 
changing the physical context  
(45; 46) 
 
Table 1. Definitions of interventions to improve antibiotic prescribing practices 
 
Persuasive interventions are e.g. performing education, audit and feedback or 
educational outreach visits. Education as an intervention might be an educational 
meeting or dissemination of educational material (39). As these interventions alone 
have showed limited impact on antibiotic prescribing practices and no sustained 
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effect, they may serve as a supplement to other interventions to improve antibiotic 
prescribing practices (33).  
Audit and feedback is “a summary of health workers’ performance over a specified 
period of time, given in a written, electronic or verbal format” (47). One example is 
to audit timing of administration of antibiotic prophylaxis to surgical patients. An 
educational outreach is “a personal visit by a trained person to health workers in their 
own settings, to provide information with the aim of changing practice” (47). 
Infectious disease (ID) physicians visiting clinical ward staff to discuss best practice 
antibiotic therapy for selected patients, is one approach for an outreach visit. Both 
audit and feedback and educational outreach interventions have shown small, but 
significant effects on professional practice (48; 49). 
Restrictive interventions can be expert preauthorisation or limited access to specified 
antibacterial agents (40). These interventions have greater short-term effect on 
antibiotic prescribing practices than the persuasive interventions, though with 
diminishing effect over time, demonstrating the usefulness of restrictive interventions 
during an outbreak of antibiotic resistant bacteria (39). 
Interventions for environmental restructuring is based on the assumption that 
antibiotic prescribing practices may change by altering the physical context, e.g. by 
implementing a tool facilitating prudent prescribing of antibiotics. Examples are the 
implementation of computerized decision support in medical records or introduction 
of new diagnostic methodology, such as rapid diagnostic testing (50; 51). 
1.2.4 Targets for optimisation of antibiotic therapy 
One way to identify the targets for optimisation of antibiotic therapy is to 




Figure 1. Targets for AMS interventions, inspired by “4 Moments of Antibiotic 
Decision Making” by Tamma et al. (52) 
In step 1, a preliminary diagnosis is made based on the patient´s history, clinical 
examination and bed side diagnostics such as urinary dipstick tests and chest 
radiographs. The clinician has to decide whether the patient is suffering from a 
bacterial infection and in need of antibiotic treatment, or whether the patient’s clinical 
condition is due to something else. An AMS intervention at this step can be 
implementing tools such as clinical pathways or rapid diagnostics, which may help 
provide a more accurate diagnosis (53). 
In step 2, a patient’s antibiotic treatment is initiated. As shown in figure 1, several 
factors should be taken in to account. The main challenge at this step is to decide the 
severity and origin of the infection. Is the patient suffering from sepsis? Is the 
infection originating from the urinary tract, the respiratory system or from another 
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organ system? Antibiotic treatment guidelines are to assist prescribers in the choice of 
correct antibiotic agent and dosing. Several publications report a lack of compliance 
with guidelines, highlighting the need to focus AMS interventions on compliance to 
guidelines (54).  
In step 3, which take place within 48 - 72 hours after initiation of antibiotic therapy, it 
is timely to review the treatment. A review means to perform a clinical assessment of 
the patient, including vital parameters as well as the patient´s clinical condition. 
Diagnostic test results, including culture results, should be available at this point in 
time, to inform further treatment options as outlined in figure 1 (55). This step 
provides an opportunity to save broad spectrum antibiotics by de-escalating to narrow 
spectrum antibiotics, or by switching from intravenous to oral antibiotics. The switch 
to oral formulations has been seen as a “low hanging fruit” in an AMS context and 
has led to several interventions, including implementation of checklists providing 
criteria for switching from intravenous to oral antibiotic treatment (56). 
In step 4, antibiotic treatment is to be discontinued. To make sure that antibiotic 
treatment is not extended longer than necessary, potential AMS measures can be the 
implementation of automatic stop orders, e.g. for antibiotics prescribed for surgical 
prophylaxis (35). Discontinuation of antibiotics as an AMS measure is also 
highlighted by an increasing number of publications showing that shorter courses of 
antibiotics are safe for several infectious diseases (57; 58).  
Other targets for optimisation of antibiotic therapy, are to review whether treatment 
prescribed for specific infectious diseases or syndromes are compliant to empirical 
treatment guidelines, such as community-acquired pneumonia or neutropenic fever, 
or to review whether the dosages prescribed are correct, e.g. for penicillins or 
aminoglycosides (35; 59). 
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1.2.5 Effects of antimicrobial stewardship interventions 
Several reviews have evaluated the effects of AMS interventions on outcomes as 
prescribing practices, patient outcomes and AMR rates (39; 60; 61). A Cochrane 
review from 2013 concluded that interventions to improve antibiotic prescribing 
practices in hospitals can reduce antibiotic resistance and improve clinical patient 
outcome (39). An update published in 2017, elaborated that AMS interventions can 
positively impact compliance with antibiotic policies and reduce duration of 
antibiotic treatment. Furthermore, it concluded that reduced antibiotic consumption 
was not associated with increased mortality and was likely to reduce length of 
hospital stay (40). In another review, Baur et al. found that AMS interventions 
reduced the incidence of antibiotic resistant bacteria when AMS interventions were 
combined with infection prevention and control measures, especially hand hygiene 
interventions (61). The studies conducted on AMS are however heterogeneous and 
several are challenged with biases, implying a need for cautious interpretation of the 
results and a strict methodology when conducting a summary review of the literature 
(60; 62).  
1.3 Diagnostic microbiology and antimicrobial resistance 
Diagnostic microbiology has two major purposes; to provide AMR surveillance data 
and to facilitate targeted antibiotic therapy to individual patients (23). Surveillance 
data are needed to gain knowledge about resistance rates that can inform antibiotic 
guidelines, but also to identify and evaluate the impact of AMR measures over time, 
although this evaluation is a complex exercise (6). Close monitoring of AMR rates in 
the individual health care institutions is necessary to discover outbreaks of 
antimicrobial resistant bacteria and promptly initiate adequate AMS- and infection 
prevention and control measures. The role of microbiology diagnostic tests in 
optimisation of antibiotic treatment to individual patients will be presented below.  
1.3.1 Development of diagnostic microbiology  
Microbiology is a relatively young discipline, shaped by Pasteur´s and Koch´s 
scientific discoveries in the late 19th century (63). Though still facing shortcomings, 
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microbiology as a discipline has undergone significant technological advances in 
recent years (64). For decades, gram staining, biochemical tests, culturing and 
antibiotic susceptibility testing have been the prevailing methods to identify 
pathogens and their antibiotic resistance patterns. More recently, molecular methods, 
such as Polymerase Chain Reaction (PCR) testing and Matrix-assisted laser 
desorption ionization- time of flight mass spectrometry (MALDI-TOF MS) have 
gained increasingly wider clinical application, primarily in identifying pathogens 
(65). These methods often have higher sensitivity and specificity, a shorter 
turnaround time and are less labour intensive compared to traditional diagnostic 
methods. However, they are more expensive and hampered by some limitations, e.g. 
PCR tests only prove the presence of a nucleic acid target and not a viable microbe 
and the MALDI-TOF MS technique cannot identify and differentiate between all 
organisms. Thus, traditional methods still have their place in diagnostic 
microbiology.  
Another progress within diagnostic microbiology is the development of rapid- or 
point of care tests. These tests are based on immunochromatographic or agglutination 
assays, and in more recent years, PCR methodology, and can identify pathogens 
within minutes or hours. However, the tests´ sensitivity vary, the number of 
identifiable pathogens are limited and antibiotic sensitivity data are scarce (66). 
1.3.2 The diagnostic pathway 
The diagnostic pathway can be a useful approach to better understand what role 
diagnostic microbiology can play to optimise antibiotic treatment in individual 
patients (Figure 2). The pathway demonstrates all the diagnostic steps from a patient 
presents with a potential bacterial infection to the use of microbiology test results to 




Figure 2. The Diagnostic pathway. Inspired by “The brain to brain turnaround time 
loop” by Lundberg and “The Diagnostic pathway” by the WHO (23; 67) 
 
In step 1, the patient with a potential infection presents before a clinician. Based on 
the patient’s history and clinical examination, a preliminary diagnosis is made in step 
2. Microbiology specimens are obtained in step 3, to provide a more accurate 
diagnosis, potentially ruling out a bacterial infection, or confirming its aetiology and 
adequate treatment options. In step 4, specimens are transported to the laboratory, 
accompanied with a request form informing the laboratory about the specimen’s 
origin and the patient history. These steps constitute the pre-analytic phase (orange 
colour). The analytic phase (green colour), take place at the laboratory. In step 5, the 
laboratory is to prepare the specimens for processing, e.g. by inoculating them on 
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agar plates, followed by analyses such as culturing, performance of biochemical tests 
and microscopy in step 6. In step 7, the laboratory is to report test results to the 
clinicians, by phone or by electronic transfer to medical records once they are 
considered significant. The results are also to inform the AMR surveillance systems 
at the laboratories, to provide an overview of the incidence of different pathogens and 
AMR rates. Next is the post-analytic phase (blue colour), initiated by step 8 where 
clinicians interpret the positive microbiology test results: Are the results relevant to 
the patient’s condition? Do the results reflect a causative pathogen or bacterial 
colonisation? In step 9, clinicians are to review the patient’s diagnosis and treatment 
in light of the microbiology test result, to tailor the treatment and thereby optimise 
patient care. 
 
1.3.3 Diagnostic microbiology and optimisation of antibiotic 
therapy 
According to the diagnostic pathway above (Figure 2) and the overview of targets for 
AMS interventions (Figure 1), microbiology test results may have a significant 
impact on antibiotic use when a review of treatment is performed. Microbiology test 
results can assist in providing a more accurate diagnosis and secure adequate 
antibiotic treatment for the patient. This is confirmed by several publications, 
showing that rapid delivery of microbiology test results can improve appropriateness 
of antibiotic prescribing, reduce antibiotic consumption, decrease length of hospital 
stay and reduce mortality rates (68-70).  
Diagnostic microbiology may also impact the initial steps of antibiotic prescribing if 
empirical antibiotic treatment guidelines are based on microbiology surveillance data. 
In addition, rapid microbiology tests may provide a more accurate initial diagnosis, 
which can help tailor and potentially narrow initial antibiotic treatment. 
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1.4 Antimicrobial resistance and antibiotic use in 
Norwegian hospitals 
The Norwegian healthcare system operates predominantly through government led 
health services and hospitals (71). All 48 Norwegian hospitals are organised in four 
regional health authorities and 20 hospital trusts, which are governed by the Ministry 
of Health and Care Services through hospital trust boards. In 2000, the Ministry 
established a surveillance programme for AMR pathogens in Norway, the Norwegian 
Surveillance System for Antimicrobial Drug Resistance (NORM-VET) (72). NORM-
VET´s latest annual report demonstrates low antibiotic resistance rates among 
humans; only 0.8% of Staphylococcus aureus blood culture isolates were resistant to 
methicillin (MRSA) and the total number of patients registered with bacteria resistant 
to carbapenems were 35 (72). The rates are increasing though, and since 2015 the 
proportion of Klebsiella isolates resistant to third generation cephalosporins (ESBL) 
has increased from 2.9% to 5.3% in 2017. Despite continuing low AMR rates, there 
has been a steady increase in broad spectrum antibiotic use (73). In 2006 and 2011, 
The Ministry of Health and Care Services established Norwegian advisory units for 
antibiotic use in primary care (ASP) and in hospitals (KAS), respectively. The units 
are to promote more appropriate antibiotic prescribing within the health care system. 
Furthermore, a national antibiotic treatment guideline for hospitals was published in 
2013 and KAS was to contribute to its implementation. The Norwegian government 
has published a strategy against AMR for the environmental-, human- and animal 
sectors in 2015 and in the following year, The Ministry of Health and Care Services 
published a National action plan on AMR in health care  (21; 74). The Action plan 
established specific outcome measures for reducing antibiotic use in both community 
and hospitals. According to the action plan, hospitals are to decrease the use of five 
specified groups of broad spectrum antibiotics by 30% by the end of 2020 compared 
to 2012. The Action plan also made it mandatory for all Norwegian hospitals to 
implement AMS programmes.  
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1.5 What are the knowledge gaps to contain antimicrobial 
resistance in hospitals? 
The introduction of this thesis has identified some key knowledge gaps that need to 
be addressed to contain development of AMR in hospitals. New research is required 
to develop novel, critical antibacterial agents and corresponding diagnostic tests. 
More research is also needed on how to increase compliance with infection 
prevention and control measures like hand hygiene, and how to optimise antibiotic 
prescribing practices (17; 18). This thesis focuses on how to facilitate optimisation of 
antibiotic prescribing practices in hospitals. 
There are large variations in antibiotic consumption rates between European 
countries, which only partly can be explained by differences in AMR rates and case 
mix (75). A variety of factors, such as sociocultural- and socioeconomically factors, 
influence prescribing practices, and their impact varies by context. It is therefore a 
necessary to understand these contextual factors in the different settings, to facilitate 
change of prescribing practices (76). Context can be understood as all internal and 
external variables that influence or could influence a phenomenon (77). 
The number of publications on optimising antibiotic use in hospitals is steadily 
increasing, but there are relatively few studies from LMIC settings and from areas 
with low resistance rates, such as Norway (31; 40). As described previously, AMS 
programmes became mandatory for all Norwegian hospitals in 2016. To facilitate the 
implementation of the programmes, it is essential to develop a better understanding of 
antibiotic prescribing practices in the Norwegian context. Thus, in this thesis, factors 
influencing antibiotic prescribing practices in Norwegian hospitals will be 
investigated. 
As highlighted previously, microbiology tests can be important tools to provide 
correct infection diagnosis and optimise antibiotic treatment, especially in hospitals. 
Several studies show that novel microbiology tests provide more rapid identification 
of pathogens, but routine reporting of test results are not beneficial for patient care 
and antibiotic prescribing practices, unless they are combined with interventions to 
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improve transferral of the test results from the laboratories to the clinical units (78). 
This indicates communication barriers between the two units, and in this thesis the 
communication barriers between the clinical units and the microbiology laboratories 
will be investigated. To our knowledge, communication barriers between these two 
units have not been explored previously.  
Finally, studies indicate that microbiology tests´ contribution to optimise patient 
treatment and containment of AMR is suboptimal due to prolonged turnaround times, 
substandard test orderings and -use of test results (79-81). Thus, knowledge is needed 
on existing microbiology test ordering practices and clinical use of microbiology test 
results, to develop targeted interventions that improve the use of microbiology test 
results. A few studies report on the yield and utility of a limited number of specific 
microbiology tests, but to our knowledge, the literature does not provide an overview 
of existing microbiology test ordering practices and clinical use of test results for 
common infectious diseases (82-84). This knowledge is warranted, and the topic will 





2. Aim and objectives  
The aim of this thesis is to gain new knowledge on factors that influence antibiotic 
prescribing practices in Norwegian hospitals, highlighting the use of microbiology 
tests. This knowledge will be applied to outline targeted interventions to optimise 
antibiotic prescribing. 
The aim will be met through the following objectives  
1. To investigate factors influencing antibiotic prescribing practices among 
Norwegian hospital physicians 
 
2. To investigate communication barriers between microbiology laboratories and 
clinical units and how they can be addressed, from a laboratory perspective 
 
3. To investigate microbiology test ordering practices in hospitals and how 






3. Design, material and methods 
3.1 Overview 
To gain new knowledge on factors that influence antibiotic prescribing practices in 
Norwegian hospitals, highlighting the use of microbiology tests, three studies were 
conducted. An overview of studies, objectives, study designs, settings and study 
participants is presented in table 2. 
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Table 2. Aims, designs, methodologies, settings and study participants for study 1-3 
 32
Development of study aims and corresponding study designs were developed 
sequentially and informed by results in the previous study. In study 1, the finding that 
delayed availability of microbiology test results was a barrier for their utilisation led 
to study 2, where this barrier was explored from a different angle, i.e. from the 
laboratory staff´s perspective. In study 2, laboratory staff questioned clinicians’ 
competencies when ordering microbiology tests and using test results. These 
perceptions were not in line with one of the findings in study 1; clinicians reported 
that they were very concerned about performing microbiology tests and using test 
results. A different study design was applied to investigate this further, through 
quantifying microbiology test order practices and use of test results in study 3.  
In the following, the methodological considerations performed to generate valid and 
reliable scientific knowledge will be presented in detail for the three studies 
constituting this thesis.   
3.2 Study 1 
3.2.1 Design and methods 
The objective of study 1 was to explore a phenomenon not previously studied in the 
Norwegian context, antibiotic prescribing practices. Thus, an explorative qualitative 
study design and interview methodology was chosen to study experiences and 
perceptions related to antibiotic prescribing practices (85-87). Interviews may be 
performed individually or in groups, termed “focus group interviews”. Individual 
interviews were preferred over focus groups interviews, as group dynamics between 
interviewees from different levels of hierarchy might prevent them to speak freely, 




3.2.2 Data collection 
Antibiotic prescribing in Norway is almost exclusively performed by physicians. 
Thus, Norwegian hospital physicians prescribing antibiotics to adult patients were 
defined as eligible participants in the study.  
Within qualitative research methodology, different sampling procedures can be 
applied and a purposeful sampling was chosen as this procedure facilitates 
recruitment of interviewees who can purposefully inform the central phenomenon 
studied, i.e. antibiotic prescribing practices (86).  
Study participants were recruited by e-mail invitations from KAS to the Directors of 
Research and Development in all the 20 Norwegian health trusts and 3 private 
hospitals. Directors accepting the invitation identified 55 eligible candidates, who 
were consecutively selected. A stratified purposeful sampling was performed to 
increase the likelihood that diverse perspectives on antibiotic prescribing practices 
emerged during the data collection (86). This means that physicians representing a 
diversity based on age, gender, specialty, clinical experience, hospital (local-, 
regional- or university hospital) and geography were included. 22 candidates were 
personally invited by e mail, and seven did not respond. A core principle when 
sampling qualitative data is sampling until data saturation, “sampling to the point at 
which no new information is obtained and redundancy is achieved” (88). This 
principle was applied together with the principle of achieving diversity among 
participants, and by 15 interviews, the criteria of data saturation and diversity were 
fulfilled. 
Before conducting the interviews, I stated my preconceptions on factors influencing 
antibiotic prescribing practices among hospital physicians in a document. 
Preconceptions are previous personal and professional motivations, experiences and 
beliefs about what is to be investigated (89). My preconceptions were principally 
constituted by my background as a clinician, being an ID physician, studying and 
working at four different hospitals nationwide. Furthermore, reviews of the existing 
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literature on hospital physicians prescribing practices contributed to my 
preconceptions (54; 75; 90; 91). 
The interviews, performed at the interviewee’s workplace between October 2013 and 
January 2014, were informed by an interview guide (Appendix 1). The interview 
guide is an instrument consisting of several open ended questions ensuring that a 
specified set of topics is covered in the interview, making the interviews “semi-
structured” (87). In this study, the interview guide was based on a literature review 
and conversations with key informants (54; 75; 90; 91). Data from the conversations 
were analysed according to the six dimensions (structural, political, cultural, 
educational, emotional and physical) of healthcare quality identified by Bate et al. 
(92). The analysis of the key informant conversations identified two additional 
dimensions (patient- and hospital) to the guide, i.e. the guide consisted of eight 
dimensions. Development of the interview guide was performed together with the 
supervisors KA and IS, whereas the interviews were recorded and transcribed 
verbatim by me. 
 
3.2.3 Analysis 
Thematic analysis was applied to analyse the interview transcripts (86; 93). Themes 
can be defined as “fundamental concepts that characterise specific experiences of 
individual participants by the more general insights that are apparent from the whole 
of the data” (94).  Subthemes were identified to provide various meanings to the main 
theme and descriptions to elaborate the meaning of the different subthemes.   
To reduce the biases of my preconceptions, the analysis was performed by an 
analytical team, consisting of two of my supervisors (KA and IS) and me. The 
analysis of the transcripts was inspired by systematic text condensation by Malterud 
and can be illustrated as shown in figure 3 (93; 94). 
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Figure 3. The process of analysing the data material 
Step 1, 3 and 5 were performed by the analytical team (dark blue), whereas step 2 and 
4 were performed by me (light blue). In step 1, the team members read the transcripts 
and independently identified potential themes. The team discussed the themes and 
consensus was made on a list of potential themes. In step 2, meaning units in the 
transcripts were identified and coded as units. A meaning unit can be defined as “a 
text fragment containing some information about the research question” (93). Coding 
means that the relevant meaning units were marked with different colours dependent 
on the themes they potentially reflected. All meaning units potentially reflecting 
identical themes were then listed in one document, followed by development of 
preliminary subthemes and corresponding descriptions. In step 3, the preliminary 
themes, subthemes and descriptions were evaluated by the team, leading to 
reorganisation, renaming and elimination of some of the themes and subthemes. In 
step 4, the new set of preliminary themes, subthemes and descriptions, were validated 
by identification of corresponding meaning units within the transcripts and adjusted 
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accordingly. In step 5, a final validation of themes, subthemes and corresponding 
descriptions were made by the analytical team. 
3.3 Study 2 
3.3.1 Design and methods  
The objective in study 2 was to explore a phenomenon, which to our knowledge has 
not been studied previously; communication barriers between microbiology 
laboratories and clinical units. Thus, an explorative qualitative study design was 
chosen, as in study 1 (85; 86). A semi-structured interview methodology was chosen 
to investigate experiences and perceptions on communication barriers (93; 94). As in 
study 1, individual interviews were preferred over focus groups to prevent the bias of 
group dynamics between interviewees from different levels in a hierarchy. 
3.3.2 Data collection 
Data collection procedures in study 2 was approximately identical to the data 
collection in study 1. Managers, physicians and technicians employed at a 
microbiology laboratory were found eligible for inclusion as the aim of the study was 
to address Norwegian microbiology laboratory staff´s perspectives. To get diverse 
perspectives from the participating laboratories, all laboratories were to be 
represented by all three professions. In Norway, 16 out of 19 microbiology 
laboratories are located at hospital trusts, and the Directors of Research and 
Development in the 16 Norwegian health trusts with a microbiology laboratory were 
invited by e-mail from KAS. A consecutive and purposeful selection of laboratories 
were performed, securing diversity in terms of hospital characteristics and geography. 
A manager, a physician and a technician from each laboratory were personally 
invited by e mail. Recruitment persisted until the criteria of diversity and saturation of 
empirical themes were fulfilled, i.e. by six laboratories and 18 interviewees (87). My 
preconceptions on communication barriers between microbiology laboratories and 
clinical units were documented before performing the interviews. As in study 1, my 
preconceptions were constituted by my background as a clinician and an ID physician 
together with my one year working experience from a microbiology laboratory as part 
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of my specialisation. Furthermore, a literature review on communication barriers 
between laboratories and clinical units, contributed to my preconceptions (64; 95-97). 
The interviews took place between January and June 2015 at the interviewees’ 
workplace. The interviews were informed by an interview guide (Appendix 2) 
developed by supervisors KA, IS and me on the basis of a literature review and 
conversations with key informants (64; 95-97). I conducted and transcribed the 
recordings in 15 interviews, whereas a technician and Master of Science student 
performed these tasks in three interviews guided by supervisor KA and myself. 
3.3.3 Analysis 
As in study 1, thematic analysis was applied to analyse the transcripts (93; 94). The 
analytical team and analytic process was identical to the one in study 1, as described 
in paragraph 3.2.3. 
3.4 Study 3 
3.4.1 Design 
To address objective 3, which was to obtain knowledge on microbiology testing 
practices and use of microbiology test results in hospitals, a quantification of test 
orders and use of test results in a cohort of hospital inpatients was performed. Thus, 
an observational cohort study design was chosen (87). 
3.4.2 Setting  
To obtain a variety in case mix, the study was conducted in the time period between 
February 10th and July 11th in 2014 in Medical departments across three emergency 
care and teaching hospitals in Western Norway. Hospital A and B were tertiary care 
hospitals with 1100 and 600 beds, respectively, offering a full range of microbiology 
testing services. Hospital C was a secondary care hospital with 160 beds, referring 
most of the microbiology specimens to hospital A. 
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3.4.3  Outcome measures 
The study´s outcome measures are listed in table 3 below. 
 
Table 3. Outcome measures in study 3 
Outcome Description 
Primary outcomes 
1: Microbiology test ordering             
    practices 
 
Measured by  
a. Degree of compliance with test ordering 
recommendations  in the Norwegian national  
antibiotic guideline, by diagnoses (98). 
b. Degree of microbiology test ordering, i.e. the 
proportion of patients who had different specimens 
obtained.  
2: Clinical use of microbiology test 
    results  
The proportion of microbiology tests ordered on the 
day of admission used to guide antibiotic therapy.  
Secondary outcomes 
1: Yield of microbiology tests  
 
The proportion of patients for which a specific test 
was positive and identified a potential causative 
pathogen.  
2: Turnaround time for     
    microbiology tests 
Time in hours from the specimen was registered as 
received at the laboratories to final test results were 
available to clinicians in the electronic medical 
record. For blood cultures; time when gram stain 
results were made available to clinicians. 
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3.4.4  Data collection 
Data was originally collected for a multicentre cluster randomised controlled 
intervention study. The original study evaluated AMS interventions in hospital 
settings in the three hospitals described above (42). In this study, inclusion criteria 
were patients being discharged after receiving antibiotic treatment. In our study, 
inclusion criteria were further limited to patients admitted for the five most common 
bacterial infectious diseases; sepsis, urinary tract infections (UTIs), skin and soft 
tissue infections (SSTIs), lower respiratory tract infections (LRTIs) or acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients 
admitted for <24 hours, >21 days were excluded in the original study (42). In our 
study, patients readmitted within 30 days were also excluded as this is defined as the 
time period required to prevent biases from a previous infection (personal 
communication, G.S. Simonsen, head of Norwegian Surveillance System for 
Antimicrobial Drug Resistance). Eligible patients were identified through patient lists 
at the wards by medical secretaries. The study population was validated by 
comparing the list of study participants with the hospitals patient registers obtained 
automatically.  
All patients were included in analyses of primary and secondary outcome measures 1 
(microbiology test ordering practices and yield). Primary and secondary outcome 
measures 2 (clinical use of test results and turnaround time) was analysed only for 
patients at hospital A, as complete microbiology test results were available at this 
hospital. To analyse primary and secondary outcome measures 2, inclusion was 
further limited to patients who had either blood-, urine-, respiratory- and/or skin and 
soft tissue cultures taken on admission, as these microbiology tests are specified as 
highly relevant for the infectious diseases studied, according to the Norwegian 
antibiotic guideline (98).  
Patient- and laboratory data, as indication for antibiotic treatment and microbiology 
test performed, were obtained from electronic- and paper medical records and drug 
charts. For primary and secondary outcome measures 1, the following microbiology 
tests were studied; blood-, urine-, respiratory- and SST cultures, as well as PCR tests 
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for viral and bacterial respiratory pathogens and urinary pneumococcal antigen tests. 
Data from the laboratory information system were obtained to study primary and 
secondary outcome measures 2. 
3.4.5 Analysis 
All outcome measures were analysed using descriptive statistics as frequencies, 
proportions, means and confidence intervals. Chi-square test was applied to compare 
testing practices between the three hospitals and Fisher's exact test when the numbers 
in one or more categories were <5. Tests were two-sided and p-values <0.01 were 
considered statistically significant as we performed multiple testing. The Statistical 
Package for the Social Science (SPSS) version 24 was used to perform the analyses. 
3.5 Ethics  
All studies were performed in accordance with the Helsinki declaration (99). The 
studies were evaluated by the Western Regional Committee for Medical and Health 
Research Ethics, which considered study 1 and 2 to fall outside the scope of the 
Committee as no patient data was obtained. For study 3, the Committee approved the 
waiver of informed consent given that written information about the study and the 
possibility for withdrawal was provided to all the patients (2013/1305). Study 1 and 3 
were also assessed by the Data Protection Officer at Haukeland University Hospital, 
who approved the studies (Study 1: 2013/6960 and Study 3: 2013/9352). The 
approval from the Data Protection Officer for study 1 was extended to apply also for 
study 2.  In study 1 and 2, all participants received oral and written information about 
the study.  As the medical community and especially the microbiology community in 
Norway is rather small, confidentiality was highlighted. Furthermore, it was 
underlined that the participants had the right to withdraw from the study for any 
reason at any time, until publication. All data were stored anonymously with an 
identification code on a research server and the key to identification stored on a 
separate domain, only available to the main supervisor. Published data was reported 
anonymously in scientific, peer reviewed journals. 
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4. Results 
4.1   Study 1 
In study 1, 15 Norwegian physicians prescribing antibiotics to adult patients were 
interviewed. The physicians were recruited from 13 hospitals and five major medical 
fields (internal medicine, surgery, oncology, neurology and intensive care). Factors 
influencing antibiotic prescribing practices were investigated and the main findings 
were as follows;  
Colleagues were identified as having a major influence on the physicians´ prescribing 
practices and several colleagues were reported as having significant influence. The 
inexperienced physicians referred to the more experienced ones, some to 
pulmonologists when treating challenging patients with respiratory infections and 
others to microbiologists to discuss microbiology test results and choice of 
antibiotics. The ID physicians were regarded as the primary collaborator when 
treating difficult infectious disease cases.  
Microbiology test results were considered as important when prescribing antibiotics 
and substantial efforts were made in obtaining cultures before initiating antibiotic 
therapy and in checking test results to inform antibiotic therapy. Delayed availability 
was perceived as a barrier for utilisation of the test results and some patients were 
discharged before physicians received the results.  
The national guideline on antibiotics was found to influence antibiotic prescribing 
practices, especially among inexperienced physicians. The guideline´s significance 
for prescribing antibiotics diminished with increasing experience and knowledge 
among the physicians and the guideline´s availability was perceived as poor. 
Training was also reported to influence physicians´ antibiotic prescribing practices. 
The training provided in the hospitals was mainly informal and unsystematic and 
frequently involved learning by observing more experienced colleagues at work and 
discussing clinical cases with them. Furthermore, assessment of patients´ clinical 
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condition influenced antibiotic prescribing practices; both patients considered to 
suffer from unclear conditions or to be severely ill, lowered the threshold for 
initiation of therapy and the prescription of broad spectrum antibiotics. Increasing 
experience facilitated more prudent prescribing. Lastly, leadership had an impact on 
antibiotic prescribing practices. Hospital leaders were perceived as absent in 
advocating antibiotic policies, but ID physicians often stepped up and filled this void 
by promoting the national antibiotic guideline and use of narrow spectrum antibiotics. 
4.2 Study 2 
In study 2, 18 employees, i.e. managers, physicians and technicians from six 
Norwegian microbiological laboratories were interviewed. Communication barriers 
between microbiological laboratories and clinical units and how these barriers could 
be addressed were investigated from the perspective of microbiology laboratory staff.  
Three major barriers were identified. Firstly, there was a disruption in the lines of 
communication between microbiology laboratories and clinical units, as illustrated by 
figure 5 below.  In the transition from pre- to post-analytic phase, disruption was 
related to specimen logistics where the process of submission was disorganised and 
poorly coordinated with the laboratories´ work processes. Laboratory staff was also 
challenged by lack of information on the request forms accompanying the specimen. 
In the transition from analytic to post-analytic phase, verbal reporting of test results 
by phone was cumbersome as the treating physicians were difficult to identify and 
laboratory staff felt unsure whether the results were acknowledged. Furthermore, 
clinical units and laboratories had different and poorly integrated information 
technology-systems and oral communication was complicated as the laboratory staff 




Figure 5. Communication between microbiology laboratories and clinical units on 
specimen processing and test results (from Paper 2) 
A second barrier identified, was mutual lack of insight into each other´s area of 
expertise. Laboratory staff perceived clinical staff as lacking knowledge on 
microbiology, and specifically on the potential and limitations of diagnostic tests. 
Concurrently, they would have liked to have better insight into patient-related issues, 
especially the laboratory technicians. They regarded their lack of insight into clinical 
work processes as challenging. It would e.g. have been valuable to understand the 
daily routines and practices for interpreting microbiology test results in the clinical 
units. Laboratory staff also wished that clinical staff had better insight into the 
internal work processes at the laboratories, e. g. the time-consuming processing of 
specimens.   
A third barrier identified, was limitations in service provision towards the clinical 
units. Insufficient funding and personnel resources was perceived to result in limited 
opening hours and advisory services, and lack of updated diagnostic technology in 
prolonged turnaround time. 
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The identification of these communication barriers highlighted a need for a review of 
the total testing process, through the pre-, analytic and post-analytic phases. A 
potential measure could be expansion of rapid and point-of-care test services. The 
identified lack of insight, pointed out a need for educational programmes for both 
clinical and laboratory staff to gain better insight to the other´s area of expertise. 
Microbiologists performing clinical outreach visits and taking part in AMS teams, 
were identified as potential facilitators for improved communication between 
clinical- and microbiology laboratory staff.  
4.3 Study 3 
In study 3, microbiology testing practices on and use of microbiological test results 
for antibiotic therapy guidance was investigated in a cohort of 1731 patient 
admissions for LRTI (35%), AECOPD (24%), sepsis (18%), SSTI (12%) or UTI 
(11%) in medical departments across three hospitals in Western Norway. 
Degree of compliance with test ordering recommendations in the national antibiotic 
guideline was 89% across all diagnoses, ranging from 81% in AECOPD patients to 
95% in sepsis patients. There was substantial additional testing beyond the testing 
recommendations, e.g. 298/606 (49%) of the patients with LRTI had a urine culture 
and 42/194 (22%) of patients with UTIs had respiratory tests.  
The yield in the total cohort was found to be 8%, 29%, 34% and 67% for blood-, 
urine-, respiratory and SST cultures, respectively. For LRTI patients, the yield for 
PCR tests detecting respiratory pathogens and urinary pneumococcal antigen was 
18% and 9%, respectively.  
A mean turnaround time of 25 hours (95% CI, 22.4-27.7) was observed for blood-, 37 
hours (95% CI, 31.2-42.6) for urine-, 56 hours (95 % CI, 49.5-63.0) for SST- and 80 
hours (95 % CI, 60.5-99.6) for respiratory cultures. 
To study use of microbiology test results for antibiotic therapy guidance, a subgroup 
of the cohort was studied. Patient admissions at hospital A from which blood-, urine-, 
respiratory- and/or skin and soft tissue cultures were taken on admission, consisted of 
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672 patient admissions. Altogether, 358/672 (53%) had negative test results and 
129/672 (19%) had non-causative findings, leaving 185 (28%) patient admissions, of 
which 65 either had findings not relevant to their diagnoses, were discharged or had 
discontinued antibiotic treatment. Thus, 120 (18%) of patient admissions had 
available, relevant test results with causative findings. Antibiotic therapy was tailored 
according to the test results only in 63 cases. In other words, antibiotic therapy was 
informed by microbiology test results in 9% (63/672) of the patient admissions. 
These findings are illustrated in figure 6.  
 
Figure 6.  Patient admissions and use of microbiology test results (from Paper 3) 
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5. Discussion 
5.1 Methodological considerations 
In the following, the strengths and limitations of the methodology used in the studies 
that constitute this thesis will be evaluated to critically interpret the generated results. 
Reliability, validity and reflexivity are core concepts that describe the quality of a 
scientific study. These concepts will structure the methodological considerations 
below. As studies 1 and 2 applied the same design and methodology, they will be 
discussed together. 
5.1.1 Study 1 and 2 
Reflexivity 
To critically display and discuss a researcher´s influence on the scientific process is 
termed “reflexivity” (87). 
As stated in chapter 3, my working experiences as a clinician and microbiology 
laboratory physician together with a literature review on the topics studied, may have 
influenced the research processes. Specifically, I documented before conducting 
study 1 that I expected to find a similar hierarchical work practice as identified by 
Charani et al. in the UK, and different perceptions on antibiotic prescribing among 
different medical specialities, as reported by Bjorkman et al. (91; 100). My 
preconceptions before conducting study 2, were mainly constituted by my 
experiences from a microbiology laboratory; I expected the laboratory technicians to 
primarily have a technical approach to the processing of specimens and being less 
concerned with the patients. Additionally, I expected the microbiology staff to be 
frustrated with lack of patient information on request forms. In sum, some of my 
preconceptions were verified, several were given nuances, and some were 
contradicted by the results from study 1 and 2. 
Furthermore, the fundraiser for this PhD, KAS, may have had an impact on the 
scientific process. KAS was established to support the Norwegian hospitals in 
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implementing AMS programmes and the national antibiotic guideline. At the time of 
decision on research aims, it was important to gain new knowledge that would be 
useful for KAS´ assignment, although there are many knowledge gaps to be filled 
within the area of AMR, as described in the introduction.  
During the interviews, my background as an ID physician and my working 
experience from a microbiology laboratory, gave me the advantage of understanding 
the interviewee´s terminology and context. My backgrounds and KAS` role in 
optimising prescribing of antibiotics, could have elicited socially acceptable 
responses from the interviewees. However, at the time of conducting the interviews in 
2014/2015, KAS was not well known among health care workers in Norwegian 
hospitals. The interviewees were not informed about KAS´ assignment and my 
clinical background to reduce this bias, but they were told upon request.  
Since I developed the interview guides and conducted and transcribed a majority of 
the interviews, there was a need to reduce the biases from my preconceptions. When 
developing the interview guides, input from the supervisors KA and IS, combined 
with information from the key informant conversations, was applied to adjust the 
interview guide. Furthermore, the analytical team consisted of me and the 
supervisors, KA and IS, expanding the perspectives for the analysis. Retrospectively, 
the analytic team might favourably have included one more professional, e.g. a 
microbiologist or a laboratory technician in study 2. For the interpretation and 
reporting of the results, several co-authors with various backgrounds, including 
international representatives, contributed with a diversity of perspectives.   
Internal validity 
Internal validity is a concept frequently associated with quantitative research designs, 
though it also applies for qualitative designs and can be defined as “whether the study 
investigates what it is meant to” (89). 
Interview methodology was applied to generate data in study 1 and 2. Observations 
provide data on behaviours and experiences as they actually occur in naturalistic 
settings, and is therefore a valuable method to supplement and validate interview data  
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(87). In study 2, several of the interviewees seemed to have difficulties describing the 
work processes within their contextual setting. Thus, observations might have added 
valuable information to elaborate and validate the results. 
The inclusion criteria for study 1, restricted inclusion to hospital physicians 
prescribing antibiotics. Although nurses and pharmacists are not prescribing 
antibiotics, they might also have been included in study1, as they are members of 
patient care teams in hospitals and probably possess valuable perspectives on 
prescribing practices. In study 2, inclusion criteria included a manager, a physician 
and a technician from each laboratory. During data collection, the interviewees made 
us aware that medical secretaries possess valuable knowledge and experiences, as 
they communicate with clinical units.  
Recruitment of interviewees in study 1 and 2 was assisted by the Directors of 
Research and Development in the health trusts, reducing potential selection bias 
exerted by the research team. However, it might be that the Directors chose 
favourable candidates particularly interested in antibiotics and AMR, skewing the 
selection. Among the suggested candidates, participants with various backgrounds 
were selected to provide diversity in perspectives reflecting different aspects of the 
research topic. Recruitment of interviewees and laboratories from all over Norway 
facilitated the fulfilment of the diversity criteria among the participants. 
As described above, recruitment continued till the criteria of diversity and saturation 
of empirical themes were fulfilled. Saturation of empirical themes is a challenging 
concept as it is dependent on the researcher´s judgement and experience (101). To 
reduce this bias, all three members of the analytic team evaluated whether saturation 
was achieved or not. 
In study 1, the six dimensions of healthcare quality (structural, political, cultural, 
educational, emotional and physical) identified by Bate et al. were used to structure 
the interview guide (92). This approach may have impacted what topics were covered 
in the interview guide and thereby influenced the results. As an example, the 
dimension “educational” may have generated the theme “training”, a theme not 
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identified in similar studies on antibiotic prescribing practices (90; 102). By 
performing key informant conversations, two additional dimensions were identified 
(patient- and hospital), adjusting the interview guide beyond the dimensions 
identified by Bate et al. The fact that we used these dimensions of healthcare quality 
and that a considerable number of studies were already published on antibiotic 
practices, made the generation of results in study 1 a more deductive process, 
whereas in study 2, there was hardly any published literature available and no 
framework was applied, which implied a more inductive analytic process. This, and 
increasing experience in scientific analysis on my part, is reflected in varying 
correspondence between interview guides and study results in the two studies. 
External validity 
External validity evaluates whether a study´s findings applies for other contexts and 
may also be termed “transferability” (89). 
The qualitative study design has limitations in terms of transferability, not providing 
representative samples. A purposeful sampling strategy facilitates identification of 
general patterns and by providing a rich, detailed description of the study context, 
researchers may evaluate whether the findings apply to other contexts as well. In 
study 1 and 2, the samples addressed a wide range of constituencies and recruited 
interviewees from all over the country. Thus, the results generated in these studies are 
likely to be valid for the Norwegian hospital setting. Whether the results are valid for 
other hospital settings is uncertain. Norway is a HIC with low rates of AMR, as are 
the Scandinavian countries and the Netherlands, and differs in this respect from many 
other countries. This may imply that antibiotic prescribing practices and use of 
microbiology tests are more similar in these countries. There is no literature to 
confirm this assumption, only indications that sociocultural factors have a significant 
influence on prescribing practices, suggesting that our results may resonate in 
countries with similar sociocultural characteristics, such as the other Northern 
European countries (75).  
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Furthermore, some findings in study 1 may represent general characteristics of 
physicians, making these specific results valid beyond the Norwegian and Northern 
European context. Studies have found that patient care is at “core for the medical 
profession” and a strong influencer on antibiotic prescribing practices (102). This is 
in line with our finding, “patient assessment” in study 1, that a patient´s clinical 
condition influences prescribing practice. 
The barriers identified in study 2, “disruption”, “lack of insight” and “limited service 
provision” are likely to exist also outside the hospital setting, i.e. in primary care and 
long-term care facilities. They too send microbiology specimens to the laboratories of 
interest in this study, but the case mix differs from hospitals, and microbiology 
laboratories are in general longer away. In addition, general practitioners may have a 
greater challenge than hospital physicians in communicating test results to patients. 
The results in study 2 are likely to resonate in other HICs, especially in countries with 
publicly funded health care systems and dispersed geography, although some specific 
challenges may vary. 




We investigated patients treated with antibiotics for one of five designated diagnoses 
that could potentially be diagnosed through six different microbiology specimens. 
The patients included were discharged from Medical departments at three hospitals in 
Western Norway through a five months period. 
A variety in case mix was ensured by including patients from three different 
hospitals. However, the selection was limited by only including from Medical 
departments and wards within three medical specialties; infectious diseases-, 
gastroenterology- and pulmonary medicine. It may be argued that these wards use a 
large amount of antibiotics and order a considerable proportion of microbiological 
specimens.  
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The inclusion period lasted from February 10th to July 11th in 2014, i.e. in part 
during the winter season. This is prime time for respiratory infections and may have 
resulted in a bias, skewing inclusion towards a larger proportion of patients with 
LRTI and AECOPD.  LRTI, AECOPD, sepsis, UTI and SSTI are the most common 
clinical conditions treated with antibiotics in hospitals. Correspondingly, only tests 
listed in the antibiotic guideline relevant to these five diagnoses were studied; blood-, 
urine-, respiratory- and skin and soft tissue samples, although the microbiology test 
repertoire is considerably larger (103).  
Data collection 
The study´s major limitation is the data collection procedures. Data was originally 
collected prospectively for another purpose, an intervention study, but were 
supplemented with additional data from the laboratory information system in the 
microbiology laboratory. 
The data sources; the laboratory information system, medical records and charts, 
were readily available and provided a complete dataset. Data in medical records and 
charts are originally registered for medical- and not scientific purposes. They are 
unstructured and have to be collected manually, leaving room for individual 
interpretations, as e.g. the parameter “indication for antibiotic treatment”, which is 
not always clearly stated in the medical records. Alternatively, diagnosis from the 
hospitals´ patient register could have been collected, but then they are registered 
retrospectively without adding any diagnostic considerations made on initiation of 
antibiotic therapy. All patient data collected was validated by a second researcher.  
Data from the laboratory information system was collected automatically, but 
turnaround time for blood cultures was calculated manually. Turnaround time for 
blood cultures was defined as the time-period from a sample arrived in the laboratory 
until the gram stain result became available, and not until the identification of 
bacteria and it´s susceptibility pattern. Concomitantly, yield was calculated based on 
positive test results identifying a potential causative pathogen. This is challenging 
concept as various clinical aspects are to be taken into consideration. As an example, 
coagulase negative staphylococci in one blood culture may be the causative pathogen 
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in a patient with a prosthesis, but considered a contaminant in a previously healthy 
patient. Our definitions were based on statements provided in the microbiology test 
result reports.  
External validity 
External- and internal validity are closely related as internal validity impacts the 
external. The multicentre design, the high number of included patient admissions and 
the long data collection period facilitated generalisability beyond western Norway, to 
other parts of Norway and potentially to other HICs with publicly funded health care 
systems. The population studied, restricted to patients admitted to Medical 
departments, may however limit the generalisability. Studies investigating antibiotic 
prescribing practices and perceptions of AMR have shown that these vary by 
countries and specialties (75; 91; 104). This may also apply to microbiology testing 
practices and clinical use of test results, thus limiting extrapolation of our results. An 
increasing number of international publications highlight the need for more targeted 
microbiology testing practices (23; 105). Our results may therefore resonate in 
several contexts, although the microbiology test ordering practices and clinical use of 
test results may vary.  
Reliability 
Reliability refers to “the accuracy and consistency of information obtained in a study” 
(106). As pointed out before, the collection of patient data could have been biased as 
the data was not structured. In addition, three researchers located at two different 
hospital sites collected the data. A potential consequence might be that the 
researchers interpreted and categorised data differently, depending on their relation to 
the hospitals, specialties or prescribing physicians.  
It is recommended to apply an acknowledged checklist when reporting on a study, so 
that readers can to assess a study´s reliability. Reporting on items, such as 
conduction, analyses and interpretations, increase transparency. To accommodate 
this, the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement—Checklist for cohort studies was applied in study 3 (107).  
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5.2 Discussion of main findings and lessons learned 
In this chapter, the results generated in the three studies constituting this thesis will be 
discussed in the light of other publications and their implications for targeting 
interventions to optimise antibiotic use in Norwegian hospitals. 
5.2.1 Expertise 
In study 1, colleagues with expertise on use of antibiotics had a major impact on 
antibiotic prescribing practices among hospital physicians, with the ID physician 
regarded as the most important advisor. ID physicians´ significance for antibiotic 
prescribing is in line with findings from various observational- and interventional 
studies conducted in HICs (108). However, several qualitative studies applying 
interview methodology have identified a strong influence on antibiotic prescribing 
practices through a medical hierarchy where clinical leaders or senior physicians 
potentially overruled ID specialist advice (109). This somehow contradicts our 
findings, and highlights the impact of social factors and context on antibiotic 
prescribing. Scandinavian works systems are characterised as egalitarian and contrast 
hierarchical works systems where expertise may be overruled by superiority (75). 
This contradiction underlines the need to perform studies on antibiotic prescribing 
practices in different contexts, to identify adequate interventions for optimisation of 
antibiotics in each context.   
The finding that expert colleagues are major influencers of antibiotic prescribing 
practices in Norway, implies that ID physicians and other experts, i.e. 
microbiologists, should be members of the AMS teams in Norwegian hospitals. Since 
ID physicians are regarded both as knowledgeable and legitimate policymakers, their 
expertise and their role as champions is essential when implementing interventions 
for optimisation of antibiotics (108). Unfortunately, not all Norwegian hospitals have 
an ID physician or microbiologist on site, but evidence shows that AMS teams can 
successfully be led by non–ID physicians or pharmacists through capacity building 
and strengthening of networks (110). Physicians in study 1 pointed out the 
significance of consulting experts when treating complicated infectious disease 
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patients. It is therefore a necessity to secure available expertise for physicians 
prescribing antibiotics, e.g. to have experienced residents or consultants in the 
emergency rooms or wards in Norwegian hospitals.   
5.2.2  Relevance of antibiotic guideline 
The national antibiotic guideline was identified as a key factor in influencing 
antibiotic prescribing practices in study 1, unlike findings in similar studies (90; 102). 
Furthermore, the more experienced and knowledgeable physicians, such as the ID 
physicians, considered the guideline as less significant than the junior physicians. 
This finding is in line with studies reporting that senior physicians are less likely to 
comply with antibiotic guidelines (109). A potential underlying explanation for the 
non-compliance could be that guidelines are considered a threat to the senior 
physicians’ professional autonomy (100; 111). This suggests that tailored audit and 
feedback on the prescribing practices of experienced physicians may favourably be 
integrated in the AMS programmes.  
Suboptimal IT-systems were found to be an external barrier that limited the 
availability of the national guideline, highlighting the need to make the guideline 
available on several platforms. Since study 1 was conducted, a pocket guide has been 
published and the comprehensive version of the guideline has become available as a 
smart phone application (98). The national guideline has not undergone a major 
update since the release in 2013, which potentially could threaten the guideline’s 
relevance and prescribers’ confidence in the guideline. However, the Norwegian 
Directorate of Health now has decided to update the guideline (112).  
5.2.3 Availability of microbiology test results 
A third key factor found to influence antibiotic prescribing practices was 
microbiology test results and their delayed availability. The delayed availability was 
perceived as barrier for utilisation of the test results, a finding coherent with other 
studies showing that delayed tests results and lack of diagnostic test facilities are 
barriers to optimal antibiotic use (90; 102). One reason why delayed availability came 
up as a major issue in our study, may be the dispersed geography in Norway, which 
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reinforces logistical challenges. This assumption was verified in study 2, where 
logistics around specimen submission and reporting of test results were reported as a 
significant barrier for the communication between clinical units and microbiology 
laboratories.  
Study 2 was conducted to get a more profound understanding of the delayed 
availability of microbiology test results, as no such studies could be found. There are 
some publications reporting on errors in laboratory medicine though, highlighting 
specimen transport and transmission of laboratory test results as critical areas, which 
resonate to our findings (80; 113). 
Interdepartmental silos may be a reason for why these communication barriers are not 
overcome. Silos are identified as impediments to quality improvement in health care, 
limiting opportunities for discussion of inadequacies and arenas for developing 
common solutions (114).  
There is a clear call to overcome the communication barriers and increase availability 
of microbiology tests to clinical staff in Norwegian hospitals, as microbiology test 
results are essential for optimising antibiotic therapy. The bottlenecks and urgencies 
may differ between the hospitals and tailored interventions should be made locally. 
However, the identified gaps in study 2 may serve as a framework when developing 
the interventions. One major communication barrier was disruption at the interface 
between the laboratories and the clinical units, highlighting the need to improve the 
transition to and from the analytical (laboratory) phase (Figure 2). This imperative is 
also in line with the Norwegian action plan on AMR in health care, which underlines 
improved logistics for specimen submission and communication of test results as an 
important AMS intervention (74). Clinical- and microbiology laboratory staff need to 
work in partnership to overcome this barrier and develop adequate and sustainable 
solutions. The AMS team may be a well suited organisational structure to facilitate 
this partnership.  
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However, not only processes at the interface between the microbiology laboratories 
and the clinical units, but also within the two units need to be addressed. The 
laboratories may reduce turnaround times by expansion of molecular diagnostics, 
rapid and point-of-care test services (78). A revision of testing processes within the 
microbiology laboratories has also shown to reduce turnaround time significantly 
(115). Moreover, the clinical units need to secure correct follow up of test results, 
with reference to study 3, showing that only half of the applicable test results were 
used to inform antibiotic therapy. 
In sum, all steps in the diagnostic pathway (Figure 2) needs to be reviewed, to 
identify measures to improve the availability and use of microbiology test results. 
Furthermore, as pointed out in the introduction, there is a call for more research on 
new diagnostics that are sensitive, affordable and with short turnaround times that can 
be applied at point of care. This would improve availability of test results 
significantly. 
5.2.4 Yield of microbiology tests 
Availability of a test results is important for their use in clinical work. Test yield is 
another aspect that influences whether a test is useful or not. In study 3, the yield of 
common microbiology tests was found to vary considerably, being in the lower end 
for blood cultures and respiratory microbiology tests. Studies investigating the yield 
for blood cultures and urinary pneumococcal antigen tests are in line with our 
findings and highlight that sampling procedures for respiratory cultures are 
challenging (82; 83; 116-118). The quality of sampling and transportation of 
specimens was not evaluated, which also may impact the yield. However, excessive 
testing practices were observed and a substantial proportion of tests sampled for the 
wrong indication contributed to a low yield. Nonetheless, although adhering to the 
guidelines when sampling specimens, the yield for several tests was low. This 
indicates that the tests´ sensitivity and specificity are poor and underlines a need to 
develop better tests to assist the diagnostic work up, especially for respiratory 
infections. Furthermore, test ordering practices should be reviewed. Obviously, 
restricting microbiology test orderings to the recommendations in the guidelines is 
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appropriate, although diagnostic uncertainty may challenge application of the 
guideline in clinical practice (84). The overall yield for blood cultures was low in our 
study, but varied significantly between patients with respiratory infections in the 
lower end and sepsis patients in the higher end. This indicates that a stratification, 
prioritising blood cultures for the more severely ill patients, may be appropriate and 
increase overall yield. To establish decision support for microbiology testing in 
computerized provider order entry systems, could be an useful approach streamline 
the test ordering practices further (119). 
5.2.5 Knowledge and insight  
Training was identified as a factor influencing prescribing practices, though mostly 
conducted informally. There are several publications indicating that apprenticeship, 
learning from masters is a common mode of adopting antibiotic prescribing practices 
in health care institutions (109). Studies also report that education and training within 
the field of antibiotic prescribing practices is highly variable, infrequent and 
insufficient (120-122). A potential explanation could be that educational activities are 
not a priority within health care as the patients` short time needs win over the long 
term benefits of education (109).  
In study 2, a lack of insight into patient-related issues and clinical work processes 
were identified among laboratory staff, and correspondingly clinical staff lacked 
insight into microbiology and laboratory work processes. In study 3, main findings 
were excessive testing beyond the antibiotic guideline´s recommendations and poor 
use of microbiology test results for therapy guidance.  
A previous study on clinical laboratory- and imaging tests reported that one third of 
tests were unnecessary and half of the relevant test results were used in patient follow 
up (81). Moreover, a study evaluating antibiotic prescribing patterns in hospitals 
found that fewer than one in three patients had their regimens narrowed, which 
resonates to our findings (123). 
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Altogether, these findings imply a need for educational programmes on infection 
management and microbiology for clinical staff such as physicians and nurses, as 
well as microbiology staff. 
Competency frameworks on appropriate antibiotic prescribing and stewardship are 
available for education and training of all health care workers (124; 125). For such 
programmes to have sustained impact on prescribing practices, education and training 
must be tailored to the context, involve local stakeholders and apply persuasive 
interventions such as audit with feedback (42; 109). Furthermore, internships may be 
valuable to increase insight among clinical- and laboratory staff into work processes 
at the microbiology laboratories and clinical units, respectively. Microbiologists 
performing clinical outreach visits provide opportunities to convey insight into 
microbiological work processes to clinical staff and to teach them adequate test 
ordering practices and how to interpret test results. In addition, the microbiologists 
can convey information on clinical processes and patient information to the 
technicians at the laboratory. 
5.2.6 Leadership 
Leadership clearly had an impact on prescribing practices, though not put forth by 
hospital leaders, but by informal leaders, i.e. the ID physicians. As described in the 
introduction, senior leadership commitment is one of the core elements in AMS 
programmes, but is not reported to be a factor influencing antibiotic prescribing 
practices (36; 90; 102). The reason for the absence of the formal leaders in promoting 
appropriate antibiotic prescribing, may be competing priorities and the absence of 
urgency related to AMR in Norway (72). However, since the interviews in study 1 
were performed in 2013/2014, the Action plan on AMR in Norwegian health care has 
been published. This plan encourages hospital leaders to take responsibility for 
reaching the set targets and they are to report to the Directorate of health on the 
specified outcome measure (74). According to ongoing audits on AMS programmes 
in Norwegian hospitals, performed by KAS since December 2017, several hospital 
leaders have taken responsibility in promoting more prudent prescribing of antibiotics 
(126). Other means to engage with hospital leaders in optimising antibiotic use could 
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be to establish specific outcome and process indicators and include AMS measures in 
hospital accreditation requirements as well as introducing financial incentives (127). 
5.2.7 Uncertainty and care for the patient 
Patient assessment influenced prescribing practices, especially when faced with an 
unresolved or severely ill patient, which is in accordance with the literature (90; 102). 
However, the patients´ influence depend on the setting. In the community- and 
private health care systems, prescribers are more motivated to fulfil patients’ 
expectations, thereby lowering the threshold for initiating antibiotic treatment. A 
review on antibiotic prescribing practices in hospitals, found that fear of losing the 
patient is a strong influencer on prescriptions, which is in line with our finding that 
the threshold for initiating antibiotics and prescribing broad spectrum antibiotics is 
lowered when a physician is inexperienced or face severely ill patients (102).  
As uncertainty and care for the patient are strong influencers of antibiotic prescribing 
practices, there clearly is a need for measures that can accommodate this uncertainty. 
Implementation of several of the interventions outlined above, may contribute to 
reduce uncertainty among prescribers of antibiotics in Norwegian hospitals, such as 
visible hospital leaders promoting prudent prescribing of antibiotics, educational 
programmes that provide the necessary knowledge and insights, available 
microbiology test results to assist in choice of adequate antibiotic therapy, a relevant, 
up to date antibiotic guideline and available support and expertise provided by 








This thesis explored factors influencing antibiotic prescribing practices in Norwegian 
hospitals, highlighting the use of microbiology tests. The findings differ somewhat 
from previous studies, which underlines the importance of performing studies in 
different contexts to identify targeted interventions for optimisation of antibiotic use 
in each context. 
To optimise antibiotic prescribing practices in Norwegian hospitals, an AMS 
programme may be a suitable organisational framework to implement these 
interventions. This thesis showed that ID physicians were perceived as trusted 
colleagues, champions for prudent antibiotic policy and played a significant role as 
clinical advisors and educators on appropriate use of antibiotics. ID physicians 
therefore have crucial role to play and should be key members of hospital AMS 
teams.  
The thesis identified that the Norwegian AMS programmes should include 
interventions to improve the use of microbiology tests. This entails to review all the 
steps of the diagnostic pathway from test ordering to reporting to use of test results. 
Microbiologists have a role to play in facilitating this review and in bridging the gap 
between clinical units and the microbiology laboratories. Thus, microbiologists 
should preferably be members of the AMS teams.  
AMS programmes in Norwegian hospitals should also establish educational 
programmes to improve knowledge in infection management and microbiology 
among clinical staff as well as microbiology laboratory staff.  
Finally, the thesis identified a need for interventions at the national level. The 
national antibiotic guideline was found to have significant influence on antibiotic 
prescribing practices, but to maintain its relevance it must remain available on several 
platforms and updated regularly. It is also necessary to make hospital leaders 
accountable for implementing AMS programmes locally and responsible for reaching 
national targets for optimised antibiotic use in Norwegian hospitals. 
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7. Suggestions for further research 
The studies constituting this thesis map barriers and facilitators to optimised 
antibiotic prescribing practices. The ID physician was reported to have a major 
influence. The literature however highlights this profession as both a facilitator and a 
barrier to prudent prescribing of antibiotics (108; 128). To utilise ID physicians as a 
facilitator, knowledge on these physicians´ perceptions and motivations for AMS 
programmes would be useful. Furthermore, nurses constitute a major workforce in 
healthcare and are a centrepiece in the caring for the infectious disease patient. They 
probably possess valuable information, contributing to the comprehensive picture on 
opportunities for optimisation of antibiotics. Thus, exploring the nurses` perspectives 
in the Norwegian context, may add useful knowledge. 
In study 3, microbiology test ordering practices and clinical use of microbiology test 
results in medical departments in Western Norway were investigated. We have not 
identified any similar study, which highlights the need to replicate the study in other 
settings to validate our findings. 
The knowledge already gained in the three studies point out several interventions to 
optimise antibiotic prescribing practices; establishment of formal education and 
training programmes, engage with hospital leaders, measures to overcome barriers in 
the communication between laboratory- and clinical units, development of new 
microbiology tests, improve testing practices and use of test results. These 
interventions are to be evaluated on outcome measures as antibiotic prescribing 
practices, patient outcomes, human resources, costs, and last, but not least AMR 
rates. 
The knowledge obtained in the three studies constituting this thesis has been valuable 
when developing AMS programmes in Norway. There is a scarcity of such studies 
from LMICs, facing even greater challenges than Norway in regard to AMR. Thus, 
investigating what influences antibiotic prescribing practices in LMICs is needed to 
implement highly warranted interventions in these countries.  
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An antimicrobial stewardship program
initiative: a qualitative study on prescribing practices
among hospital doctors
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Abstract
Background: Norway has a low, but increasing prevalence of resistance and few antimicrobial stewardship
initiatives. When developing stewardship interventions, an understanding of the determinants of antimicrobial
prescribing is needed. We report on the first qualitative study investigating factors influencing doctors’ antimicrobial
prescribing practices in Norwegian hospitals.
Methods: Qualitative semi-structured interviews were conducted with 15 Norwegian hospital doctors prescribing
antimicrobials to adult patients. Interviews were transcribed verbatim and thematic analysis was applied to analyse
the data.
Results: Colleagues, in particular infectious disease specialists, microbiology test results and the newly published
national guideline on antimicrobials were identified as key factors influencing antimicrobial prescribing practices.
Delayed availability was a barrier for the utilization of microbiology test results and increasing clinical experience
overrides the influence of the national guideline.
Patient assessment, informal training by experienced colleagues, and infectious disease specialists replacing
managers in promoting prudent prescribing policies, also influenced prescribing practices.
Conclusion: This study identified the following contextual factors that need to be addressed when developing
antimicrobial stewardship programs in Norway: a common work practice for seeking collegial advice, logistics of
microbiology test results, and formal leadership and systematic training on prudence. Other countries initiating
stewardship programmes may benefit from performing a similar mapping of facilitators and barriers, to identify
important stakeholders and organisational obstacles, before developing sustainable and tailored antimicrobial
stewardship interventions.
Keywords: Antimicrobial use, Prescription practices, Hospital doctors, Antimicrobial resistance, Antimicrobial
guideline, Qualitative research
Background
Though several countries have antimicrobial stewardship
programmes (ASPs) in place [1], many are initiating
stewardship activities, including such diverse countries
as India and Norway [2, 3]. In Norway antimicrobial
resistance (AMR) rates are low, but increasing, and
antimicrobial consumption, in particular broad spectrum
antimicrobials, has increased the last 20 years [4, 5]. In
2013, overall sales of antimicrobials were 20.0 Defined
Daily Doses (DDD) per inhabitant per day. Hospitals are
responsible for around 7 % of the total antimicrobial
consumption [4].
The increasing national and international threat of
AMR has highlighted the need for interventions to
contain the low rates of AMR in Norway [3]. In an up-
coming Norwegian action plan for containment of AMR
mandatory components of ASPs and audits assessing the
quality of the prescriptions will be addressed, filling the
present void. “The National Advisory Unit for Antibiotic
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Use in Hospitals” (KAS) is to coordinate these initiatives
in Norwegian hospitals.
The Norwegian healthcare system operates predomin-
antly through government led health services and hospitals.
The country has a dispersed geography with many small -,
some medium- and a few large university hospitals. Many
of the smaller hospitals lack on-site microbiology laborator-
ies and infectious disease specialists (ID-specialists). Fur-
thermore, clinical microbiologists and -pharmacists are not
established professions, leaving antimicrobial prescribing
decisions to be made by doctors alone. In July 2013, a new
national guideline on antimicrobials was published, re-
placing local guidelines [6]. The guideline was developed
with contribution from over 80 hospital doctors, mainly
ID- specialists and is only available online.
ASPs have proven to be efficient in the short term, with
no clear evidence of what are the successful components
for a sustainable change in prescribing practices [7, 8]. A
systematic review of antimicrobial prescribing studies in
hospitals suggests that sustainability of ASPs may be
improved with a better understanding of behavioural
determinants of prescribing [9]. Another review concludes
that cultural, contextual and behavioural factors need to be
addressed to influence antimicrobial use [10]. Both qualita-
tive and quantitative studies have been performed on the
topic [11–18], however, we report on the first qualitative
study in Norway investigating factors influencing anti-
microbial prescribing practices among hospital doctors.
Methods
Study design
An explorative qualitative design using a semi-structured
interview methodology was chosen to investigate factors
influencing antimicrobial prescribing practices among
hospital doctors [19, 20]. Face to face interviews were pre-
ferred over focus groups to reduce bias of social pressures
between informants’ positions and specialities, preventing
them from expressing their opinions freely.
Study interview guide development
An interview guide was developed based on a literature
review and individual face to face conversations with six
key informants (hospital doctors), purposively sampled
from two hospitals in Western Norway [10, 13, 21, 22].
Open ended questions were used to conduct the conversa-
tions. The six dimensions (structural, political, cultural,
educational, emotional and physical) of healthcare quality
identified by Bate, Mendel and Robert were applied as a
framework to analyse data from the conversations and
structure the interview guide [23]. Analysis of the key in-
formant conversations identified two additional dimen-
sions to the guide (patient- and hospital characteristics)
and informed the detailed questions of the interview guide
(full interview guide in additional file 1).
Recruitment of participants
Author IS (study project manager) requested the Directors
of development and research in all health trusts in Norway
via e-mail to invite individuals to participate in the study.
Some disseminated the invitation by e-mail asking for
volunteers, and others selected candidates from the list
of employees. Only doctors prescribing antimicrobials
to adult patients and working in hospital wards were
qualified for inclusion, including ID-specialists.
Initially, 55 doctors were identified by the Directors of
development and research as eligible to participate in
the study. To secure a rich diversity, 22 of them were
consecutively selected based on age, gender, specialty,
clinical experience, hospital (local-, regional- or university
hospital) and geography. Author BS informed the 22
doctors about the study and personally invited them to
participate by e-mail. Seven doctors did not respond to
the invitation. Saturation of empirical themes was reached
after ten interviews, however, to fulfil the criteria of diver-
sity, 15 doctors were interviewed [24, 25].
Interviews
Interviews took place between October 2013 and January
2014. All interviews were recorded and transcribed verba-
tim. Author BS, an ID-specialist and PhD student trained
in qualitative methods conducted and transcribed the in-
terviews. They were performed at the participants’ work
place within working hours. The participants were not in-
formed about the interviewers’ background, but were told
if they asked.
Analysis
Thematic analysis was applied to the transcripts using a
combined deductive and inductive approach [20, 26, 27].
Two researchers (BS, IS) read all the transcripts independ-
ently, and a third researcher (KA) read a major sample of
them. The three researchers independently listed the
emerging themes and through discussions agreed on pre-
liminary themes. One researcher (BS) identified quotes in
all the transcripts reflecting each theme and developed
preliminary subthemes. Subsequently quotes reflecting
each subtheme were categorized, and corresponding de-
scriptions were developed. Themes, subthemes and de-
scriptions were then discussed by the three researchers,
leading to reorganising, renaming and elimination of some
themes and subthemes. This procedure was then repeated
for themes and subthemes requiring further analysis. Final
conclusion on themes, subthemes and descriptions were
conducted through discussions and agreements between
all three researchers (Table 2).
Ethics
The Regional Committee for Medical and Health Research
Ethics considered the study to only need approval by the
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Data protection officer representing The Norwegian Data
Protection Authority, from which it was approved (2013/
6960). All interviewees signed an informed consent.
Results
Fifteen doctors from 13 hospitals and five major medical
fields (internal medicine, surgery, oncology, neurology and
intensive care) were interviewed. Two of the interviewees
were ID- specialists (Table 1). Duration of interviews
ranged from 36 to 68 min (average 54 min).
The participants describe an antimicrobial prescribing
practice in Norwegian hospitals which mainly involve in-
terns and residents (doctors training to become specialists).
In smaller hospitals, interns are the only doctors present in
the emergency departments, whereas in bigger hospitals
they work alongside residents. Normally interns discuss
patients with residents who, when lacking sufficient
knowledge and experience, discuss the patients with
consultants. Consultants receive updates on hospitalized
patients on morning and afternoon handover meetings.
Antimicrobial treatment initiated in patients hospitalized
during daytime is evaluated on evening rounds by a resi-
dent or a consultant on call. At hospital wards, consultants
in general play the role of supervisors and attend ward
rounds at variable frequencies. ID-specialist services
vary greatly between hospitals. Some have ID-specialist
consultants on-site, who perform counselling by phone
or bedside, and may do systematic ward rounds, for in-
stance at intensive care units. Other hospitals lacking
ID-consultants obtain advice by phone from hospitals
possessing this expertise. Nationwide ID-specialists are
available by phone day and night all year.
In the following, we will use the six main themes that
emerged from the analysis to describe the key factors
influencing hospital doctors’ practice when prescribing
antimicrobials; colleagues, microbiology test results,
national guideline, training, patient assessment and
leadership (Table 2).
Colleagues
In daily clinical work, more experienced doctors are fre-
quently consulted regarding antimicrobial therapies. When
local expertise is insufficient, an ID-specialist is the desired
colleague to seek advice from, mainly by phone, exemplified
by the following quote: “Concerning antibiotic treatment,
we follow a simple algorithm, but when things get com-
plicated, we collaborate with the ID-specialists, and in-
tensive care doctors, of course” (C1). The ID-specialist
can also exert influence during handover meetings,
through discussions regarding antimicrobial treatment
of hospitalized patients.
Other specialities can also be influential, including pul-
monologists and nephrologists when treating patients
with pneumonia or kidney failure. Microbiologists may
impact antimicrobial prescription when clinicians phone
them for test results and choice of antimicrobials is dis-
cussed. One interviewee described the involvement of dif-
ferent colleagues in antimicrobial prescribing as follows:
“Working as a junior doctor, I first phone the consultant on
call. However, often you end up phoning the resident on
call at the department of internal medicine. Occasionally
they can give you some advice, or they consult their consul-
tants. A couple of times I have called the ID-specialist at
the University hospital“(C2).
Microbiology test results
Doctors actively use microbiology test results when
selecting antimicrobial therapy. Firstly, they emphasize
obtaining specimens before starting antimicrobial treatment
(M1). Secondly, they put a great effort into checking up on
results, in order to adjust treatment. Lack of availability and
timeliness is perceived as a limiting factor since test results
are first made available when resistance data are complete
(M2). In hospitals without a microbiology laboratory there
is also the delay of specimen transport and transfer of re-
sults into separate electronic systems, leading to prolonged
broad spectrum antimicrobial treatment, and patients being
discharged before results are available. Clinicians try to
overcome these obstacles by phoning the laboratory for
preliminary test results (M2, M3), and laboratories phone
clinical departments about important results such as
positive blood cultures. However, opening hours of the
laboratories are usually limited from morning to afternoon,
six to seven days a week.
Table 1 Demographics of participants
Variable numbers
Male/female 7/8
Age 25–35 years 6
Age 36–45 years 5
Age 46–55 years 2





Other medical fieldsb 3
Health trusts represented 9/20
Local hospitals represented 6
Regional hospitals represented 5
University hospitals represented 4
aOrthopedic, gastrointestinal, urology, gynecology
bOncology, neurology, intensive care
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Table 2 Description of the identified themes
Quotes Description Subthemes Themes
Concerning antibiotic treatment, we follow a simple
algorithm, but when things get complicated, we
collaborate with the ID-specialists, and intensive care
doctors, of course. [Consultant, gastro surgery] (C1)
The ID-specialist is the primary collaborator when treating
difficult infectious disease patients
ID-specialists Colleagues
Working as a resident, I first phone the consultant on call.
However, often you end up phoning the resident on call at
the department of internal medicine. Occasionally they can
give you some advice, or they consult their consultants. A
couple of times I have called the ID-specialist at the
University hospital. [Resident, oncology] (C2)
When the ID-specialist is not readily available several
other colleagues contribute to the choice of AB-treatment;
More experienced colleagues in the wards and on call,
internists, especially pulmonary doctors and microbiologists
can provide input on AB treatment
Other
colleagues
We put great effort into obtaining specimens, preferably
several specimens, in order to be sure that we use an
adequate antifungal and not just Fluconazole. Our experience
is that we more frequently, more often use other drugs, but
then again, in accordance with resistance data. [Consultant,
intensive care] (M1)
Microbiology test results are considered an important
contribution to the treatment; Great effort is put into
obtaining cultures and to check up on the preliminary
results in order to adjust treatment accordingly.
Priority Microbiology
test results
If it has not been transferred to the electronical medical
record, it’s not there. But it’s there. They are just waiting for
the final resistance data. In other words, the test results are
there, but it takes two or three days before they show up
on the screen. So maybe.., yes. No, people just need to
know that they can make a phone call. [Resident, internal
medicine] (M2)
Microbiology reports become available very late to the
clinician. The clinician tries to solve this by phoning to
the lab, and vice versa.
Availability
Our systems do not let us check up on what tests have
been obtained. You actually have to call and ask: “Have
you received the specimen so and so?” Or else, you would
have to wait for the results for another two to three days.
Once it is available, it is shown in the electronical medical
record in the section for laboratory results. [Consultant,
ID-specialist] (M3)
It’s perfectly okay as long as you use it, you’re safe. No
one can hold anything against you as long as you treat
according to the guideline. It really makes you feel safe
when on call. [Intern, internal medicine] (N1)
When knowledge and experience are insufficient, the
guideline is perceived as a useful and supportive tool.
The guideline’s significance however decreases with
increased experience and knowledge.
Experience National
guideline
Well, I try to stick to the guideline, most of the time. If I
do not, I normally have good reasons not to. But, I do
not always agree with it. And I try to justify it if I do not
follow it. [Consultant, ID-specialist] (N2)
The computer works incredibly slow here. It is very
annoying when logging on, that is. You just sit there
and twiddle you thumbs for… That’s when it would
have been great to have an app, just great. [Intern,
internal medicine] (N3)
Suboptimal IT-systems impairs the availability of the
guidelines. Distribution on several platforms would
promote the availability
Availability
..we have checklists for items they have to check out. And
the antibiotic guideline is one among them. That’s how we
somehow tell them this is to be complied with, and also
to be sure that they know how to find it. [Consultant,
internal medicine] (N4)
The guideline is used to promote AB policy Promoting
policy
Education mainly takes place at the end- of- shift meetings,
that is. Much is embedded in each of the cases we discuss.
[Consultant, orthopedics] (T1)
Training is mainly informal and unsystematic; Lectures are
held irregularly. However, training comes mainly from





Discussing with ID-specialists, but also observing how other
doctors on call treat patients and discussions at the end-
of- shift meeting. [Resident, internal medicine] (T2)
There is no scheduled training, no. You’re expected to
possess that knowledge, which you don’t have as an
intern, because, it’s too theoretical. To have a guideline,
-it is presented to you early on.. Just check the guideline,
just use it. And you end up reading about it yourself. [Resi-
dent, internal medicine] (T3)
The national guideline is used as a substitute for the
formal training
Guideline
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National guideline
The national guideline is considered a useful tool by in-
terns and inexperienced residents (N1). One less experi-
enced doctor refers to the time period from when the
local guideline was outdated until the new national
guideline was published as follows: “When I was told
that the guideline was outdated I panicked. What am I
going to do, what am I going to use now? Fortunately,
the new ones were then published.”
More experienced residents use the guideline as a ref-
erence for checking dosages and treating uncommon
infectious diseases, whereas consultants, including ID-
specialists, consider the guideline as less significant and
emphasize the need to adjust treatment to individual
patients (N2). They consider the guideline as a tool and
not a law, and may point out its weaknesses.
The availability of the guideline is limited due to sub-
optimal IT-systems. Computers may be slow and the
guideline hard to find, which is time consuming. Some
participants therefore expressed a desire to have a print
out, a pocket guide or a smart phone application (N3).
Some doctors describe that the guideline is used as a tool
to promote antimicrobial policy. Informal leaders (ID-
specialists), and to a lesser extent formal leaders (hospital
managers), point to the guideline as a national and local
standard for antimicrobial treatment. This is especially
stressed to new employees e.g. interns and locums (N4).
Training
Lectures and courses in antimicrobial use are held,
though irregularly. However, input from more experienced
clinical colleagues is the most valued type of training (T1).
Inexperienced doctors empasize supervision by experi-
enced doctors when on call in the emergency room,
and experienced doctors highlight discussions with
ID-specialists. Learning may also come from sheer obser-
vation of how more experienced colleagues prescribe anti-
microbials (T2).
The national guideline is used as a substitute for formal
training. Experienced doctors or managers may refer to it
as a useful tool to the less experienced. One resident said:
“There is no scheduled training, no. You’re expected to
possess that knowledge, which you do not as an intern,
because it’s too theoretical. To have a guideline, -it is
presented to you early on… Just check the guideline,
just use it. And you end up reading about it yourself” (T3).
Patient assessment
The influence of patient assessment on antimicrobial
prescribing becomes evident in several settings. Firstly,
Table 2 Description of the identified themes (Continued)
Sometimes, in the emergency department when your
findings are inconclusive, you broaden the initial therapy.
They keep telling me: “Try not to use broad spectrum as
much,” but once in a while you just have to, and it’s is
okay to a certain degree. Patient first, so to speak. [Intern,
internal medicine] (P1)
When patient history, findings and diagnostic tools are
inconclusive it feels safer to prescribe antimicrobials, than






It depends on clinical judgement, and the patient’s clinical
condition. If he is in very bad condition, fulfilling all the
sepsis criteria, and has an unstable blood pressure and
everything, only the broadest spectrum. [Consultant,
urology] (P2)
Severity of disease determines the intensity of treatment;
Threshold for starting AB, prescribing broad spectrum
agents and prolonging therapy is lowered
Severity of
disease
No, I’m not quite sure whether I can call it politically
incorrect, but severely ill neutropenic patients are given
Meropenem although it’s possible that they shouldn’t be
given any antibiotics at all, but at the same time I think
that… [Consultant, internal medicine] (P3)
I may have become better at waiting. In most cases, you
have much more time than you expect. And in that case,
you can wait until you know some more. [Resident, internal
medicine] (P4)
Clinical experience facilitates dealing with the challenging




No, it’s not on the agenda, that’s my experience. My
impression is that we are free to do as we like. But, it
doesn’t mean that we can go crazy. I think it would have
been pointed out if we were to give everyone everything. I
think it would have been put on the agenda. [Consultant,
ID-specialist] (L1)
AB policy is to a small extent on the agenda of the
hospital leaders
Priority Leadership
NN is the leader of the infectious disease department, and
he is on every end-of-shift meetings and so on. And it’s
very.. people always say: “We give this and that, and I’m
not sure that the ID-specialists agree.” And they sit there,
and give corrections, or say: “Yes, but we have to resort to
that,” or.. [Resident, internal medicine] (L2)
The ID-specialists advocates prudent AB use in discussions
about clinical cases, typically on morning sessions.
ID-specialists
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when patient history, findings and diagnostics are incon-
clusive, or when infection is difficult to distinguish from
cancer or rheumatic disorders, it feels safer to prescribe
antimicrobials than not, and broad spectrum therapy is
often chosen to secure adequate coverage (P1). Secondly,
severely ill patients suffering from sepsis or significant
comorbidities are often treated more aggressively with
regard to initiation, spectrum, de-escalation and duration of
antimicrobial therapy (P2, P3). Clinical experience facilitates
dealing with these patients. According to the interviewees,
experience makes it easier to identify the severely ill
patients and to prescribe antimicrobials prudently (P4).
The confidence to rely on narrow spectrum antimicrobials
as adequate treatment for several severe conditions is only
acquired with experience.
Leadership
Hospital managers are not perceived as promoting anti-
microbial policies. An ID-specialist said: “No, it’s not on
the agenda, not that I know. My impression is that we
are free to do as we like, but that doesn’t mean that we
can “go crazy”. I think it would have been pointed out if
we were to give everyone everything. Then it would have
been put on the agenda” (L1). However, ID-specialists fill
the void of managers and advocate prudence by promoting
the guideline and the use of narrow spectrum antimi-
crobials, typically on handover meetings while discussing
clinical cases (L2).
Discussion
When exploring factors influencing hospital doctors’
antimicrobial prescribing practices the main themes
identified were microbiology test results, colleagues
and the antimicrobial guideline. Some of these results
differ from what has been found in previous studies
[11, 13, 28], and some have implications for the successful
implementation of an ASP.
The most interesting finding was the participants’
emphasis on microbiology test results when prescribing
antimicrobials and their frustration over delayed results.
This has to our knowledge not been highlighted in previ-
ous studies. Experienced hospital doctors in Germany
viewed microbiologists and laboratories as helpful in
navigating antimicrobial treatment, but delayed results
were not mentioned as a challenge [29]. A reason why
delay came up as a major issue in our study may be the
dispersed geography in Norway. Transferrals of specimens
between hospitals and results back to the clinicians pose a
major logistical challenge. Action to improve the line of
communication between the laboratories and the clinics,
both electronically and orally, is required to enhance
support of clinical antimicrobial decision making. Fu-
ture research should explore how leaders and staff at
microbiology laboratories perceive the interaction with
clinicians, as a basis for possible interventions on these
lines of communication. Furthermore, studies show that
antimicrobial stewardship teams can decrease time to
appropriate therapy by close follow up of microbio-
logical test results [30, 31], so establishing such teams
in Norwegian hospitals is highly relevant.
Another major finding was the influence of colleagues
on antimicrobial prescribing practice. Two studies con-
ducted in Ireland and UK found a hierarchical system
where senior colleagues had significant influence on
prescribing practices of the doctors [28, 15]. Another
study from the UK report on a prescribing etiquette
where clinical leaders and senior doctors overrule the
ID-specialists’ advice on antimicrobials [11]. On the
contrary, our interviewees spoke of several colleagues
as legitimate advisers, the ID-specialist being regarded
as the superior. In accordance with our findings, a
Swedish study found that all categories of doctors per-
ceived the ID-specialists as important for antimicrobial
prescribing and –resistance [12], and may express what
is described as egalitarian Scandinavian work systems
with a corresponding low consumption of antimicrobials
[10]. Since our interviewees are responsive to advice from
ID-specialists and ID-specialists are found to improve ap-
propriateness of antimicrobial prescribing, they should be
included in multidisciplinary antimicrobial stewardship
teams [32]. However, many Norwegian hospitals lack ID-
specialists, as well as clinical pharmacists and microbiolo-
gists, i.e. the traditional participants of ASP teams [33]. As
a consequence, ASP teams may have to be staffed differ-
ently in the Norwegian model. Studies have shown that
antimicrobial stewardship initiatives can be developed
without the traditional staffing, structures and resources
[34, 35]. The integration of nurses and other medical spe-
cialties should therefore be further explored in Norway.
A third major finding was that the doctors’ attitudes
towards the national guideline correspond with level of
clinical experience. Whereas interns and inexperienced
residents are dependent on the guideline, senior doctors
are more sceptical to it, which is in accordance with
other studies [36, 37]. One interviewee, an ID-specialist,
reported that he did not adhere to the guideline even
though he had participated in developing it. This lack of
adherence among senior doctors may be due to clinical
autonomy and experience [11, 38]. In Norway it may
also be explained by a gap in exposure to ASP interven-
tions. Being on the brink of initiating nationwide ASP
programmes, tailored audit and feedback to experienced
doctors on prescribing and application of the guideline,
may favourably be integrated in the programmes.
Furthermore, participants in the study report that their
managers do not promote prudent use of antimicrobials.
In hospitals with ID-specialists they may take the place
of managers and promote prudence. However, when
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implementing an ASP, a formal leadership is considered
essential to maintain the program [33]. Providing
knowledge on AMR to raise awareness supplemented
with local surveillance reports on antimicrobial use and
-resistance, may be a useful strategy to engage with
Norwegian hospital managers [39]. Another way to
promote prudent antimicrobial prescribing practice
could be to introduce formal and systematic training
programmes [40, 41], especially for interns. Improved
availability of the guideline is crucial and work is under
way to provide access to the guideline in pocket guide
and smart phone application formats.
The study has a few limitations. As interviewees were
recruited by the Directors of development and research
there may be a bias towards candidates with a special
interest in antimicrobials.
Furthermore, the role of author BS (conducting inter-
views), being an ID-specialist, may affect the response
from the participants and the interpretation of the results.
However, this was tentatively handled by writing down
preconceptions before conducting the interviews and
by involving three authors with different backgrounds
in crucial steps of the data analysis.
The sample of 15 interviewees met the methodological
requirement of saturation of themes and diversity [24].
The sample addresses a wide range of constituencies as
hospital size, age and professional background, securing
diversity. ID-specialists’ prescribing practices differs sig-
nificantly from other doctors’. We considered it important
to include them in order to obtain a comprehensive
picture of the antimicrobial prescribing practices in
Norwegian hospitals.
Conclusion
Our study has identified several contextual factors that
influence antimicrobial prescribing in Norway, many which
differ from those reported from other countries. These
factors, such as a common work practice for seeking
collegial advice, logistics of microbiology test results,
and formal leadership and systematic training on prudence,
need to be addressed when developing ASPs. This dem-
onstrates the value of conducting a qualitative mapping
of contextual factors before establishing antimicrobial
stewardship initiatives. Other countries planning to im-
plement ASPs may benefit from a similar mapping of
facilitators and barriers, to identify important stake-
holders and organisational obstacles, before developing
sustainable and tailored ASP interventions.
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Background: Many countries are on the brink of establishing antibiotic stewardship programmes in hospitals na-
tionwide. In a previous study we found that communication betweenmicrobiology laboratories and clinical units
is a barrier to implementing efficient antibiotic stewardship programmes in Norway. We have now addressed
the key communication barriers between microbiology laboratories and clinical units from a laboratory point of
view.
Methods: Qualitative semi-structured interviews were conducted with 18 employees (managers, doctors and
technicians) from six diverse Norwegian microbiological laboratories, representing all four regional health
authorities. Interviews were recorded and transcribed verbatim. Thematic analysis was applied, identifying
emergent themes, subthemes and corresponding descriptions.
Results: The main barrier to communication is disruption involving specimen logistics, information on request
forms, verbal reporting of test results and information transfer between poorly integrated IT systems.
Furthermore, communication is challenged by lack of insight into each other’s area of expertise and limited pro-
vision of laboratory services, leading to prolonged turnaround time, limited advisory services and restricted open-
ing hours.
Conclusions: Communication between microbiology laboratories and clinical units can be improved by a review
of testing processes, educational programmes to increase insights into the other’s area of expertise, an evalu-
ation of work tasks and expansion of rapid and point-of-care test services. Antibiotic stewardship programmes
may serve as a valuable framework to establish thesemeasures.
Introduction
In Norway, implementation of antibiotic stewardship programmes
(ASPs) is in its early stages.1 One of the core elements of ASPs is ac-
cess to microbiology laboratory services.2,3 Microbiology laborato-
ries are critical in surveillance of antibiotic resistance, development
of empirical antibiotic treatment guidelines and guidance of clin-
ical staff in the diagnosis and treatment of infections. Rapid deliv-
ery of microbiology test results has been shown to influence
mortality, length of hospital stay and costs, as well as appropriate-
ness of antibiotic prescribing and consumption, which are the
main drivers for development of antibiotic resistance.4–7 In a previ-
ous study on antibiotic prescribing in hospitals, we found that clin-
icians perceived communication of microbiology test results as
inadequate anda barrier to effective antibiotic stewardship.8
Processes involving communication between laboratories and
clinical units are the most error-prone parts of laboratory test-
ing.9,10 Up to 30% of adverse events in laboratorymedicine impact
patient care and up to 12% of the events cause actual or potential
harm to patients.11,12 Taking into account the high volume of test-
ing, such errors may significantly affect patient safety and public
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the
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health globally, highlighting the need to review laboratory testing
processes.
Norway has a dispersed geography with a variety of small, me-
dium and large hospitals. There are 48 hospitals nationwide, of
which 45 are public. Only 16 hospitals have on-site microbiology
laboratories andhospitalswithout themsend samples to the near-
est hospital with such facilities. All laboratories are open during the
daytime 6–7 days a week. Some hospitals provide a microbiology
service in the evening, but none during the night. This evidently
challenges communication between themicrobiology laboratories
and the clinical units.
Based on our previous findings that clinicians were dissatisfied
with the communication between microbiology laboratories and
clinical units, we proceeded to study the communication between
the two from a laboratory point of view. In this study we investi-
gate communication barriers between microbiology laboratories
and clinical units, and how they can be addressed. To our know-
ledge this is the first published study on this topic.
Methods
Study design
A qualitative design, using semi-structured interview methodology, was
chosen to study the question of communication barriers betweenmicrobiol-
ogy laboratories and clinical units, and how these barriers can be
addressed.13,14 In order to reduce any bias from social pressures between
informants’ positions, individual interviewswere preferred over focus groups.
Interviews
An interview guide was developed based on a literature review and on indi-
vidual face to face conversations with four key informants (a manager, a
doctor, a technician and a secretary), using open-ended questions.15–18
The informants were purposely sampled from amicrobiology laboratory in
western Norway. The interview guide covered the following topics: process-
ing of specimens, roles, education/experience, communication, leadership
and improvementmeasures.
Interviewees in the study were recruited by a request sent to the direc-
tors of research and development at the 16 hospitals in Norway with a
microbiology laboratory. Eight laboratories responded positively. Inclusion
continued until two criteria, saturation of empirical themes and diversity,
were met.19,20 Ultimately, six laboratories were included, purposely se-
lected based on hospital characteristics (teaching/non-teaching) and geog-
raphy, securing representation from all four regional health authorities.
A manager, a doctor and a technician were recruited from each of the six
laboratories to obtain diversity of perspectives. The participating managers
weremainly technicians byprofession (Table 1).
InterviewswereperformedbetweenJanuaryand June2015at the inter-
viewees’ workplace within working hours. They lasted from 46 to 86min
(mean 64min), were recorded and transcribed verbatim. Author B. S., an
infectious disease specialist and PhD student trained in qualitativemethods,
conducted and transcribed 15 interviews, whereas author A. L. B., a techni-
cian and MSc student, conducted and transcribed 3 interviews under super-
vision of authors B. S. and K. A.
Analysis
Thematic analysis was applied to the transcripts through the following
steps:13,14,21 authors K. A., I. S. and B. S. (analytic team) read all the tran-
scripts and independently listed emerging themes. Discussions led to an
agreement on preliminary themes. Subsequently, author B. S. identified
quotes reflecting each theme and developed preliminary subthemes and
corresponding descriptions of subthemes. Preliminary themes, subthemes,
descriptions and quotes were then discussed, resulting in elimination, re-
organization, renaming and reformulation of some of them, before a final
validation by the team. Translation of the results fromNorwegian to English
was conducted through discussions and agreements in the analytic team
and co-author E. C.
Ethics
The study was approved by the Data Protection Officer at Haukeland
University Hospital, representing the Norwegian Data Protection Authority
(2013/6960). The Regional Committee for Medical and Health Research
Ethics considered the study to fall outside the committee’s scope as no pa-
tient data were obtained. An informed consent form was signed by all
interviewees.
Results
The interviewees describe the processing of specimens in three
steps: pre-analytical, analytical and post-analytical. Technicians
are mainly responsible for the pre-analytical and analytical steps,
butmay consultmicrobiologistswhenneeded, andmicrobiologists
mainly perform the post-analytical steps (Figure 1). All laboratories
use electronic laboratory information systems (LIS) to store sam-
ple data and transfer test results to electronicmedical records.
In Norway, microbiologists are normally laboratory based, al-
though some perform clinical ward rounds once or twice a week.
Microbiology laboratories communicate with clinical units during
all three steps, but more so on transition to and from the pre- and
post-analytical steps. The interviewees described processing of
specimens and corresponding communication with clinical units
as illustrated in Figure 1.
Following data analysis, three main themes emerged that de-
scribe the barriers to communication between microbiology and
clinical units: ‘disruption’, ‘lack of insight’ and ‘limited service provi-
sion’ (Table 2). These identified barriers subsequently identify po-
tential channels to improve communication. ‘Disruption’ is easily
identified at the pre- and post-analytic steps, whereas the
themes ‘lack of insight’ and ‘limited service provision’ are add-
itional barriers to communication that relate to processing of spe-
cimens (Figure 1).
Disruption
The interviewees describe communicationwith clinical units as dis-
ruptive. Firstly, disruption is related to logistics and request forms
at the pre-analytic step. Secondly, there is disruption in verbal re-
porting of test results at the post-analytic step. Thirdly, communi-
cation is interrupted by poorly integrated laboratory and clinical IT
systems (Figure 1).
Table 1. Demographics of participants
Governmental microbiology laboratories
represented
6 out of 16
Regional health authorities represented 4 out of 4
Local/regional/university hospitals represented n"2/n"2/n"2
Male/female n"4/n"14
Technician/doctor/manager n"6/n"6/n"6
Aged 25–35/36–45/46–55/56–65 years n"4/n"3/n"6/n"5
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Transfer of specimens from clinical units to the laboratories is
complicated and time consuming, and specimen arrival is poorly
coordinated with laboratory work processes. As a consequence,
specimens gomissing, showup after several days or arrive too late
to be processed the sameday (quotes D1 andD2 in Table 2). These
are everyday challenges, but becomemore evident for specimens
transferred from hospitals without a microbiology laboratory, par-
ticularly on weekends and holidays. These delays and their poten-
tial consequences for individual patients are of great concern to
the interviewees.
‘My main concern regarding local hospitals is transport.
Specimens are transported by bus for one and a half hours.
It shouldn’t be a big problem, but submission of specimens
must correspond with the bus schedule. During holidays
such as Christmas and Easter, when everything is closed for
days, time is spent figuring out how to submit the specimens
as the hospital is not to spend money on taxis. So, occasion-
ally important specimens are not submitted, before they are
long overdue.’ (Manager) [D1]
Furthermore, incomplete information on microbiology request
forms adds to the workload and delays initial specimen
processing.
‘Very often there is only a name on the microbiology request
form, or hardly that, a name and a date of birth. We do not
know what kind of specimen it is, who has sent it, we don’t
know anything. So the guessing game begins; we check up
on the electronic patient record and make a lot of phone
calls, which of course is error prone.’ (Technician) [D3]
Themain challenge at the post-analytical step is reporting significant
test results to clinical staff by phone. Identification of who is the
treating doctor or nursemay be difficult. There is also uncertainty as
towhether the results are acted upon [D4]. The concern ofmicrobiol-
ogy laboratory staff is that important information is left outwhen re-
sults are passed on from one person to another. Consequently, ward
nurses,whoare readily available by phone,maybebypassed in order
to convey the results directly to the clinician concerned [D5]. Since
cliniciansmaybehard tofind, e.g. surgeonsareoften in theoperating
theatre, preliminary electronic results are provided to ensure transfer
of important information to the clinical units.
All written exchange of information between laboratories and
clinical units is based onelectronic transfer, except for paper-based
request forms for bacterial culture. However, information transfer
is inadequate due to poorly integrated IT systems between the
laboratories and the clinical units. Since technicians are not famil-
iar with the electronic medical record and the final result displays
differently in the two systems, oral communication around test re-
sults becomes complicated.
‘I got a question I did not understand until someone told me
that “their screen display is different from ours”.—“Oh, is
that so?”—I didn’t have a clue. I have never seen the elec-
tronical medical record. One of my colleagues had seen it,
and she also found it difficult to interpret.’ (Technician) [D6]
This disruption in electronic information transfer leads to excess
phone calls to the laboratory to clarify the results.
Lack of insight
When microbiology laboratory staff communicate with clinical
staff, they perceive amutual lack of insight into each other’s work:
clinical staff lack insight into microbiology and laboratory work
processes, and laboratory staff lack insight into patient-related
issues and clinical work processes.
Firstly, microbiology laboratory staff report that many doctors
and nurses do not fully understand the potential, but also the limi-
tations, of microbiology tests. Furthermore, some of them have
poor knowledge as towhen to take a test and how to interpret the
test results.
‘I think that sometimes clinicians take a lot of specimens
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Table 2. Description of the identified themes
Theme Subtheme Description Quote
Disruption specimen logistics the process of specimen submission is
difficult to follow, in part time con-
suming and poorly coordinated with
the laboratory work processes, in par-
ticular for specimens from local
hospitals
‘My main concern regarding local hospitals is transport. Specimens
are transported by bus for one and a half hours. It shouldn’t be a
big problem, but submission of specimens must correspond with
the bus schedule. During holidays such as Christmas and Easter,
when everything is closed for days, time is spent figuring out how
to submit the specimens as the hospital is not to spend money on
taxis. So, occasionally important specimens are not submitted, be-
fore they are long overdue.’ (Manager) [D1]
‘Specimens from local hospitals have to arrive by eight thirty for them
to be processed in the Maldi in the morning. Frequently specimens
arrive at nine thirty–ten, and we cannot sit and wait for them, but
have to process the submitted specimens in order to give out their
results. It’s a shame really, for the patients, that’s for sure.’
(Technician) [D2]
request forms inadequate information onmicrobiology
request forms complicates and delays
the initial specimen processing
‘Very often there is only a name on the microbiology request form, or
hardly that, a name and a date of birth. We do not know what kind
of specimen it is, who has sent it, we don’t know anything. So the
guessing game begins; we check up on the electronic patient re-




reporting test results over the phone
represents a challenge in identifying
the clinician concerned and making
sure the significance of the result is
acknowledged
‘Yes, blood cultures can be challenging. If you’re not, if you can’t get
hold of the requesting clinician, the result is pending out there
somewhere. Nobody knows who the clinician concerned is, you
know. We always make phone calls when blood cultures are posi-
tive. It may be fatal if we do not get hold of a doctor.’ (Technician)
[D4]
‘Regarding significant test results, I may bypass nurses, . . . It may be
crucial to talk to the clinician directly, to avoid information being
misplaced.’ (Microbiologist) [D5]
IT systems the laboratory and the wards have dif-
ferent and poorly integrated IT sys-
tems, and microbiology lab personnel
are not familiar with the electronic
patient record system
‘I got a question I did not understand until someone told me that
“their screen display is different from ours”, “Oh, is that so?”—I
didn’t have a clue. I have never seen the electronical medical re-
cord. One of my colleagues had seen it, and she also found it diffi-
cult to interpret.’ (Technician) [D6]
Lack of
insight
microbiology a majority of clinical personnel are per-
ceived as having insufficient know-
ledge of microbiology
‘I think that sometimes clinicians take a lot of specimens hoping that
we can give them a diagnosis. For instance, nowadays we are
inundated with throat specimens from the emergency depart-
ment.’ (Microbiologist) [I1]
work processes clinical personnel often lack insight into
the laboratory’s work processes, and
microbiology lab personnel wish they
had more insight into the clinical work
processes
‘They are used to getting clinical lab results within an hour or two, but
with regard to microbiology results we have to explain to them
that it takes one day for the bacteria to grow, and then another
day for susceptibility testing. They don’t get it, and. . .’
(Microbiologist) [I2]
‘I don’t know how doctors interpret the test results. For instance, a
urine specimen where numbers are low, do they interpret it as a
urinary tract infection?’ (Technician) [I3]
the patient microbiology lab personnel lack patient
contact and insight into clinical
conditions
‘If you work at a microbiology laboratory and never have been on the
wards, you will know that blood cultures are important as well as
spinal fluid, but you don’t know HOW important until you’ve seen a
patient suffering frommeningitis, for instance. So I think this is an




personnel resources insufficient personnel resources limit
opening hours and advisory services
towards clinical staff
‘You know, our opening hours are restricted. And every day, when we
arrive at work there are missed calls on the phone. People have
tried to call us during the evening, but there is no one there.
Continued
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nowadays we are inundated with throat specimens from the
emergency department.’ (Microbiologist) [I1]
Microbiology staff also express that clinical staff lack insight into
the internal work processes of the laboratories. More specifically,
they lack awareness of the need to provide good-quality speci-
mens to the laboratory, and have limited knowledge of how speci-
mens are processed in the laboratories, expressing their frustration
overwhat they call ‘delayed test results’.
‘They are used to getting clinical lab results within an hour or
two, but with regard to microbiology results we have to ex-
plain to them that it takes one day for the bacteria to grow,
and then another day for susceptibility testing. They don’t
get it, and . . .’ (Microbiologist) [I2]
At the same time,microbiology staff, especially technicians, would
like to havemore insight into clinical work processes, e.g. what are
the daily routines on the wards? How are microbiology test results
interpreted and applied [I3]? However, microbiologists with some
clinical training sometimes act as interpreters. Technicians also ex-
press a lack of insight into patients and clinical conditions. They do
not meet patients themselves, in contrast to technicians at a clin-
ical biochemistry laboratory who obtain specimens on the wards.
Furthermore, they have limited access to patients’ medical history
and clinical condition.
‘If you work at a microbiology laboratory and never have
been on the wards, you will know that blood cultures are im-
portant as well as spinal fluid, but you don’t know HOW im-
portant until you’ve seen a patient suffering frommeningitis,
for instance. So I think this is an area that should be ad-
dressed.’ (Technician) [I4]
The interviewees point out that it would have been valuable to
have such insightwhenprocessing specimens or discussing test re-
sultswith clinical staff.
Limited service provision
The overall aim of laboratory staff is to provide services beneficial
for the patients. However, a barrier to optimal communication
with clinical units is limited personnel resources and lack of
updated diagnostic technology.
The workforce is too small to keep the laboratories open and
provide a 24h service and limited opening hours are of great con-
cern to the interviewees.
‘You know, our opening hours are restricted. And every day,
when we arrive at work there are missed calls on the phone.
People have tried to call us during the evening, but there is
no one there. Unfortunately, staffing and budgets do not
allow us to be open 24/7, though I know that larger laborato-
ries and some smaller labs elsewhere offer a better and
wider range of services.’ (Manager) [S1]
They know that patients suffer from infectious diseases day and
night and report that they frequentlywork late to complete test re-
sults, in order tomeet requests from clinical staff.
The laboratory staff considers teaching and advisory services to
be a significant part of their service provision to clinical units. For in-
stance, ad hoc teaching on the phone on when and how to obtain
specimens and choice of antibiotics is prioritized. To give lectures
on microbiology for clinical staff is also considered essential; how-
ever, limited personnel resources restrict educational outreach
[S2]. Services are further limited by lack of updated diagnostic
technology, such as MALDI-TOFs, resulting in prolonged specimen
turnaround time.
‘If we were to have a MALDI-TOF, test results could be pro-
cessed quicker, at least the ID of microbes. And, when mo-
lecular biological methods expand, with increased resources
and equipment, it will contribute to a shorter turnaround
time for test results. I suppose it will impact patient care and
budgets in general. For instance, for MRSA patients who are
Table 2. Continued
Theme Subtheme Description Quote
Unfortunately, staffing and budgets do not allow us to be open
24/7, though I know that larger laboratories and some smaller
labs elsewhere offer a better and wider range of services.’
(Manager) [S1]
‘Some technicians do hold lectures in clinical units on how to obtain
specimens among other things, which is good. However, we don’t
do it often due to lack of time to prepare the lectures. Laboratory




insufficient diagnostic technology pro-
longs turnaround time
‘If we were to have a MALDI-TOF, test results could be processed
quicker, at least the ID of microbes. And, whenmolecular biological
methods expand, with increased resources and equipment, it will
contribute to a shorter turnaround time for test results. I suppose
it will impact patient care and budgets in general. For instance, for
MRSA patients who are isolated while waiting for the test results,
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isolated while waiting for the test results, rapid diagnostics
make a difference.’ (Technician) [S3]
Discussion
The results from this study highlight key communication barriers
betweenmicrobiology laboratories and clinical units froma labora-
tory point of view. Disruption at the interface between laboratories
and clinical units, mutual lack of insight into each other’s area of
expertise and limited laboratory services are all barriers that need
to be addressed in order to improve the communication.
To address disruption between laboratories and clinical units, the
entire testing process from sampling of specimens to application of
test results needs to be reviewed. For instance, specimen logistics are
neither transparent nor adapted to technical developments within
the laboratories, indicating a need for joint revision on submission of
specimens. Communicationof significant test results by phone is also
found to be inadequate. As a consequence, vital test resultsmay not
be received by the treating clinicians, a situation that poses a patient
safety threat. This highlights a need for common routines on who is
to receive test results and how. Furthermore, there is a need for bet-
ter integrationbetween the IT systemsat the laboratoriesandclinical
units, especially at the post-analytical step, with improved presenta-
tionof test results in theelectronicmedical record.
It is not only processes at the interface between themicrobiology
laboratories and the clinical units that need to be addressed, but
also processes within these units. A previous study showed that
turnaround time could be significantly reduced by improved com-
munication between staff running the MALDI-TOFs and staff at the
molecular laboratory.22 Another study from across the United
States found that follow-up of abnormal test results in clinical units
is inadequate.23 A joint effort, where all the steps in the testing pro-
cess are addressed, has the potential to reduce turnaround time.
This would improve availability and timeliness of microbiology test
results, which has been reported to be a barrier to implementing ef-
ficient antibiotic stewardship programmes.8
Limited microbiology services are also perceived as a barrier.
Both limited personnel resources and lack of updated diagnostic
technology prolong turnaround time and restrict advisory services
and opening hours. However, new rapid microbiological tech-
niques are evolving, to some extent replacing traditional culturing
and susceptibility testing, which over time may reduce the need
for personnel resources in the analytical processes.24 In addition,
revision of testing processes and more adequate testing may im-
prove workflow and workload, thereby releasing personnel re-
sources to provide guidance to clinical staff.
Limited opening hours could be addressed by expansion of on-
site and around the clock services, and the use of rapid diagnostic
tests, such as immunochromatography- and PCR-based tests for
detecting respiratory tract pathogens.25 However, the sensitivity
and specificity of these tests vary and validation and quality con-
trol of these tests should be performed by a core microbiology la-
boratory. Although new rapid tests are evolving, traditional
methods such as Gram staining of blood isolates may also impact
patient treatment.24 Establishing these servicesmay be of particu-
lar significance at hospitals without microbiologists, potentially
reducing turnaround times of blood isolates significantly.
To enhance quality control, externalmicrobiologistsmay supervise
local clinicians via tele-microbiology services, e.g. when interpret-
ing Gramstains.18,26
The mutual lack of insight into each other’s area of expertise is
a barrier closely related to disruption. Educational programmes
with lectures combinedwithmutual internships for laboratory and
clinical staff could contribute to a better understanding of comple-
mentary work processes and give laboratory staff insight into pa-
tient conditions. These perspectives also need to be integrated into
the undergraduate education of laboratory and clinical staff.27
Establishing ASPs in hospitals can be an efficient framework to fa-
cilitate some of the suggestedmeasures to improve communication
and increase insight between microbiology laboratory and clinical
staff. ASP teams are multidisciplinary and should preferably be
staffed by microbiologists and infectious disease physicians.8,28 In
performing antibiotic stewardship outreach visits in clinical units,
microbiologists can enhance their role as interpreters of clinical proc-
esses and patient information to the technicians at the laboratory.
Such visits also provide an opportunity to convey insight into micro-
biology and microbiological work processes to clinical staff, and
teach them how to interpret test results.29 As microbiological meth-
ods evolve and become increasingly sophisticated, the need for pro-
fessional guidance will increase.30 This may require a change in how
somemicrobiologists execute their profession, frombeingpredomin-
antly laboratory based toworkingmore closelywith clinical staff.31
This study was performed in the Norwegian hospital setting;
however, the findings are likely to resonate in all healthcare set-
tings, although the specific challengesmay vary. There is reason to
believe that disruption in specimen logistics and verbal reporting of
test results also poses a challenge for long-term care facilities and
family physicians. In contrast to long-term care facilities, there are
reports from family physicians indicating the presence of such bar-
riers. Family physicians have an additional communication chal-
lenge in that they have to notify their patients of test results.32,33 A
review of the communication between microbiology laboratory
and clinical staff is therefore valuable in a variety of clinical
settings.
In this study we performed individual interviews; however, it
could be argued that observations in the laboratories would have
added valuable information.34,35 Furthermore, according to the
interviewees, medical secretaries at the laboratories may possess
valuable experience regarding communication with clinical staff
and could have been included as interviewees. The sample is
dominated by females as they constitute themajority of thework-
force in Norwegian laboratories. Finally, authors B. S. and A. L. B.,
being an infectious disease specialist and a technician, respect-
ively, may have affected the response from the participants during
interviews and interpretation of the results. However, by docu-
menting preconceptions and performing analyses with amultidis-
ciplinary scientific team, this limitationwasmanaged.
Conclusions
In order to address the barriers to communication betweenmicro-
biology laboratories and clinical units there is a need for a joint ef-
fort to improve disruption at the interface of the two units through
a review of testing processes. We further recommend educational
programmes to mutually increase insights into each other’s area
of expertise, an evaluation of work tasks, and expansion of rapid
and point-of-care test services to further improve laboratory
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services. ASPs may serve as a suitable framework to establish
these measures, and thereby enhance communication between
microbiology laboratories and clinical units.
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Abstract
Background: Effective use of microbiology test results may positively influence patient outcomes and limit the use
of broad-spectrum antibiotics. However, studies indicate that their potential is not fully utilized. We investigated
microbiology test ordering practices and the use of test results for antibiotic decision-making in hospitals.
Methods: A multicentre cohort study was conducted during five months in 2014 in Medical departments across
three hospitals in Western Norway. Patients treated with antibiotics for sepsis, urinary tract infections, skin and soft
tissue infections, lower respiratory tract infections or acute exacerbations of chronic obstructive pulmonary disease
were included in the analysis. Primary outcome measures were degree of microbiology test ordering, compliance
with microbiology testing recommendations in the national antibiotic guideline and proportion of microbiology
test results used to inform antibiotic treatment. Data was obtained from electronic- and paper medical records and
charts and laboratory information systems.
Results: Of the 1731 patient admissions during the study period, mean compliance with microbiology testing
recommendations in the antibiotic guideline was 89%, ranging from 81% in patients with acute exacerbations of
chronic obstructive pulmonary disease to 95% in patients with sepsis. Substantial additional testing was performed
beyond the recommendations with 298/606 (49%) of patients with lower respiratory tract infections having urine
cultures and 42/194 (22%) of patients with urinary tract infections having respiratory tests. Microbiology test results
from one of the hospitals showed that 18% (120/672) of patient admissions had applicable test results, but only half
of them were used for therapy guidance, i.e. in total, 9% (63/672) of patient admissions had test results informing
prescription of antibiotic therapy.
Conclusions: This study showed that despite a large number of microbiology test orders, only a limited number of
tests informed antibiotic treatment. To ensure that microbiology tests are used optimally, there is a need to review
the utility of existing microbiology tests, test ordering practices and use of test results through a more targeted and
overarching approach.
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Background
Effective use of microbiology test results has been shown
to influence patient outcomes, health care costs and ap-
propriateness of antibiotic prescribing and – use [1–3].
Microbiology tests have also for years provided anti-
microbial resistance (AMR) surveillance data, informing
empiric antibiotic therapy guidelines. With increasing
AMR rates globally, sensitive, specific and affordable
microbiology tests could be important tools in providing
targeted antibiotic treatment to patients. The tests may
facilitate de-escalation of antibiotic therapy from broad-
to narrow spectrum treatment, thereby limiting the se-
lection of drug resistant bacteria.
However, several studies indicate that the potential of
microbiology tests is not fully utilized. Firstly, clinicians
feel they cannot make full use of microbiology tests due
to prolonged turnaround times (TATs) [4, 5]. Secondly,
although many guidelines provide microbiology test or-
dering recommendations and information on how to in-
terpret and use test results [6, 7], studies show that
microbiology test ordering and use of test results are
substandard [8–11]. As diagnostic microbiology methods
evolve and become more sophisticated, these inadequa-
cies may increase and ultimately result in incorrect anti-
biotic treatment for patients, as well as inefficient use of
human and laboratory resources [12].
There are some studies on yield and utility of blood cul-
tures, skin and soft tissue (SST) cultures, urinary pneumo-
coccal antigen (UPAg) and polymerase chain reaction
(PCR) tests detecting respiratory pathogens, and evidence
exists for excessive ordering of urine cultures in asymp-
tomatic patients [13–17]. However, there is little know-
ledge on existing microbiology test ordering practices and
clinical use of microbiology test results, which is needed to
optimize use of the tests. The aim of our study was there-
fore to investigate microbiology test ordering practices in
hospitals and how microbiology test results were used to
inform antibiotic decision-making. Our hypotheses were
that a majority of current microbiology test ordering prac-
tices did not adhere to recommendations in the national
antibiotic guideline and that a minority of microbiology
test results were used to guide antibiotic treatment.
Methods
Design, setting and study population
This study was a multicentre cohort study conducted in
infectious diseases-, gastroenterology- and pulmonary
medicine wards across three emergency care and teach-
ing hospitals in Western Norway. Patient data were ori-
ginally collected for a multicentre cluster randomized
controlled intervention study, evaluating antibiotic stew-
ardship interventions in hospital settings [18].
Hospital A and B were tertiary care hospitals with
1100 and 600 beds, respectively, offering a full range of
microbiology testing services. Hospital C was a second-
ary care hospital with 160 beds, referring the majority of
microbiology specimens to hospital A. Infectious dis-
eases- and pulmonary medicine wards were selected as
these specialties have the highest consumption of antibi-
otics and thus order a large proportion of microbiology
tests. Gastroenterology was included since hospital B
had a joint medication storage area for the pulmonary
medicine- and gastroenterology wards.
Microbiology test ordering practices were analysed
using data from patients discharged from the study wards
between February 10th and July 11th 2014. Only data
from patients receiving antibiotic treatment for sepsis,
urinary tract infections (UTIs), skin and soft tissue infec-
tions (SSTIs), lower respiratory tract infections (LRTIs) or
acute exacerbations of chronic obstructive pulmonary dis-
ease (AECOPD) was included in the analyses. Patients ad-
mitted for < 24 h, > 21 days and/or readmitted within 30
days were excluded. Clinical use of test results was ana-
lysed for patients at hospital A, as complete microbiology
test results were available at this hospital.
Outcome measures
The primary outcome measures were microbiology test
ordering practices and clinical use of microbiology test
results. The secondary outcome measures were yield and
TAT for the microbiology tests (Table 1).
Data collection
Patient data, including indication for antibiotic treat-
ment, antibiotic treatment throughout the hospital
stay, allergic reactions to antibiotics, glomerular filtra-
tion rate and number of days admitted were obtained
from medical records and drug charts. Indications for
antibiotic treatment were based on the treating physi-
cians’ working diagnoses as recorded in patients’
medical records or drug charts on the day of initi-
ation of antibiotic treatment. Laboratory data were
collected from medical records to evaluate microbiol-
ogy test ordering practices and yield, and from the la-
boratory information system to study clinical use of
microbiology test results and TAT (Table 1). An over-
view of microbiology tests and test results are pre-
sented in Table 2. Bacterial cultures were identified
by matrix assisted laser desorption ionization-time of
light mass spectrometry (Maldi-Tof MS) and suscepti-
bility testing was performed by disk diffusion tests or
by minimum inhibitory concentration gradient tests.
The PCR tests were developed in-house and the
UPAg test was a lateral flow immunoassay.
Data analysis
Descriptive statistical analyses were performed on all
outcome measures (Table 1). Chi-square test was
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applied to evaluate differences in microbiology testing
practices between the hospitals, where the testing fre-
quencies of each hospital were compared to the total test
frequency of the two others. Fisher’s exact test was applied
when numbers in one or more categories were < 5. Tests
were two-sided and because of multiple testing, p-values
< 0.01 were considered statistically significant. Statistical
analyses were performed using the SPSS (Statistical Pack-
age for the Social Science) version 24.
Results
In total, 1731 patient admissions were included in the
analyses of microbiology test ordering practices. The
mean age was 68 years old (range 15–103 years), the
female/male ratio was 0.48/0.52, mean length of stay
was 6.8 days and the 30 day-mortality rate was 8%
(142/1731). The distribution of diagnoses was as
follows: LRTI 35%, AECOPD 24%, sepsis 18%, SSTI
12% and UTI 11% (Table 3). Of the total patient co-
hort, 48% were recruited from Hospital A, 27% from
Hospital B and 25% from Hospital C.
Guideline adherence
The degree of compliance with microbiology test order-
ing recommendations in the national antibiotic guideline
was 89% across all diagnoses. Compliance was 95% in
sepsis (blood culture), 92% in UTI (urine culture), 88%
in LRTI (PCR test detecting respiratory pathogens,
UPAg test, respiratory- or blood culture) and 81% in
AECOPD (respiratory- and/or blood culture). There
were no specific test ordering recommendations for
SSTIs, however culture specimens were often obtained
from the site of infection.
Testing practices by tests, diagnoses and hospital sites
Many patients had more than one microbiology sam-
ple collected regardless of diagnosis (Table 3). In the
total cohort of patient admissions, the following
microbiology tests were ordered: 76% blood cultures,
54% urine cultures, 49% respiratory tests and 9% skin
or soft tissue cultures. Among the patients with LRTI
and AECOPD, 49 and 41% had urine cultures taken,
respectively. Concomitantly, 22% of the patients with
UTI had respiratory tests performed. Test ordering
practices varied between the three hospitals. Patients
diagnosed with sepsis, LRTI and AECOPD had sig-
nificantly more respiratory tests taken at hospital B
than at the two other hospitals (p < 0.01), and the
same groups of patients had significantly less respira-
tory tests taken at hospital C compared to the two
other hospitals (p < 0.01).






a. Degree of compliance with test ordering recommendations in the Norwegian national antibiotic guideline,
by diagnoses [6].
b. Degree of microbiology test ordering, i.e. the proportion of patients who had different specimens obtained within
the first three days after initiation of antibiotic treatment, by diagnoses and hospital sites
2: Clinical use of microbiology
test results
The proportion of microbiology tests ordered on the day of admission used to guide antibiotic treatment. Use was
assessed within the first two days after tests results were available to clinicians.
For an antibiotic regime to be defined as adjusted in accordance with microbiology test result, it had to be susceptible to
the identified pathogen and the regime least prone to drive antibiotic resistance. The evaluation took into account
glomerular filtration rate and allergic reactions to antibiotics as recorded on admittance.
Secondary outcomes
1: Yield of microbiology tests The proportion of patients for which a specific test
was positive and identified the potential causative pathogen. Reported by test and diagnoses.
2: Turnaround time for
microbiology tests
Time in hours from the specimen was registered as received at the laboratories to final test results were available to clinicians
in the electronic medical record. For blood cultures; time when gram stain results were made available to clinicians.
Table 2 Overview of microbiology tests and test results
Microbiology tests
Respiratory tests Respiratory cultures
Polymerase chain reaction (PCR) tests for viral and
bacterial respiratory pathogens
Urinary pneumococcal antigen tests
Skin and soft
tissue cultures




Positive findings Potential pathogen identified
a) Causative
findings
Positive test results identifying causative pathogen
b) Non-causative
findings
Positive test results reported as “contaminants”,
“normal flora” or “mixed flora”
Negative findings No pathogen identified
Skodvin et al. Antimicrobial Resistance and Infection Control            (2019) 8:28 Page 3 of 8
Yield
The total yield for blood-, urine-, respiratory- and SSTI
cultures was 8, 29, 34 and 67%, respectively (Table 4).
For blood cultures, the yield was 20% in sepsis- and 4%
in LRTI patients. For LRTI patients, the yield of the PCR
test detecting respiratory pathogens, UPAg test and re-
spiratory cultures was 18, 9 and 33%, respectively. How-
ever, 52% of the respiratory cultures had non-causative
findings.
Turnaround time
Mean TAT was 25 h (95% CI, 22.4–27.7) for blood-, 37 h
(95% CI, 31.2–42.6) for urine-, 56 h (95% CI, 49.5–63.0)
for SST- and 80 h (95% CI, 60.5–99.6) for respiratory
cultures.
Clinical use of test results
In hospital A, there were 828 patient admissions, of which
81 collected microbiology specimens at day > 1 after admis-
sion, leaving 747 cases eligible for inclusion in the analyses
of clinical use of microbiology test results obtained on the
day of admission. Of these, 672 (81%) had blood-, urine-,
respiratory- and/or SST cultures taken and were included
in the analyses of clinical use of test results (Fig. 1).
Of the 672 patient admissions, 358 (53%) had nega-
tive microbiology test results and 129 (19%) had non-
causative findings. Among the remaining 185 cases, 37
had findings not relevant to their diagnoses, four had
stopped antibiotic treatment and 24 were discharged
when microbiology test results became available. Of the
120/672 (18%) inpatients with applicable findings, anti-
biotic treatment was adjusted according to test results
only in 63 patients, i.e. 9% of the total number of pa-
tient admissions. Among the patients with the diagno-
ses SSTI and UTI, a majority had their antibiotic
treatment adjusted in accordance with the test results,
whereas treatment was adjusted only in a minority of
the patients with AECOPD. As only 120 patient admis-
sions had applicable test results, the number in each
diagnostic group was low.
Table 3 Microbiology test ordering practices
Microbiology test
Blood culture Urine culture SST culture1 Resp. test2
Diagnosis* Hospital % p3 % p3 % p3 % p3
Sepsis Hospital A n = 205 95.1 0.64 70.2 0.02 10.7 < 0.01 60.0 < 0.01
Hospital B n = 42 88.1 0.06 76.2 0.81 2.4 0.34 78.6 < 0.01
Hospital C n = 73 97.3 0.38 86.3 0.01 1.4 0.02 17.8 < 0.01
Total n = 320 94.7 74.7 52.8 7.5
UTI Hospital A n = 67 59.7 0.77 91.0 0.64 3.0 0.27 31.3 0.02
Hospital B n = 50 70.0 0.05 90.0 0.54 2.0 1.00 36.0 < 0.01
Hospital C n = 77 49.4 0.04 94.8 0.28 0.0 0.28 3.9 < 0.01
Total n = 194 58.2 92.3 1.5 21.6
SSTI Hospital A n = 97 80.4 0.97 14.4 < 0,01 68.0 < 0.01 8.2 0.66
Hospital B n = 54 79.6 0.89 13.0 0.04 44.4 0.16 11.1 0.22
Hospital C n = 52 80.8 0.92 50.0 < 0,01 32.7 < 0.01 1.9 0.12
Total n = 203 80.3 23.2 52.7 7.4
LRTI Hospital A n = 287 80.8 0.07 48.4 0.73 1.0 0.51 68.3 < 0.01
Hospital B n = 164 75.0 0.36 40.2 0.01 1.8 0.71 89.0 < 0.01
Hospital C n = 155 74.2 0.25 60.0 < 0,01 1.9 0.70 20.0 < 0.01
Total n = 606 77.6 49.2 1.5 61.6
AECOPD Hospital A n = 172 74.4 < 0.01 38.4 0.42 2.3 0.46 59.3 0.29
Hospital B n = 152 57.9 0.01 33.6 0.02 1.3 1.00 92.1 < 0.01
Hospital C n = 84 63.1 0.54 58.3 < 0.01 1.2 1.00 14.3 < 0.01
Total n = 408 65.9 40.7 1.7 62.3
All Total n = 1731 76.1 53.7 8.7 49.3
*AECOPD: acute exacerbation of chronic obstructive pulmonary disease; LRTI: lower respiratory infection; SSTI: skin and soft tissue infection; UTI: urinary tract infection
1SST culture: wound, pus, breastmilk or tissue culture
2Resp. test: respiratory culture, polymerase chain reaction (PCR) test for viral and bacterial respiratory pathogens and/or urinary pneumococcal antigen test
3p value for testing whether there is a significant difference between one hospital compared to the total frequencies of the two others by Chi-square test or by
Fisher’s exact test when numbers in one or more categories were < 5
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Discussion
The main finding of this study was that despite a large
number of microbiology test orders, only a small frac-
tion of test results informed antibiotic decision-making.
We observed high compliance with test ordering recom-
mendations in the national guideline, but excessive test-
ing across diagnoses, contributing to a low yield. TATs
were long and microbiology test results with causative
pathogens were underused, both contributing to the low
utilization of the tests.
To our knowledge, this is the first study reporting
on microbiology test ordering practices and use of
test results in clinical practice. A previous study on
clinical laboratory- and imaging tests, reported that
one third of tests were unnecessary and only half of
relevant test results were used in patient follow up
[11]. Studies investigating the yield of blood culture
and UPAg tests, showed similar results to ours [13,
14, 19, 20]. The high rates of respiratory cultures with
non-causative findings identified in our material are
also in accordance with the literature, reporting that
respiratory sampling procedures are challenging [21].
Our study shows that the existing microbiology tests,
testing practices and use of test results are not in accord-
ance with the objective of microbiology testing; only a
minor fraction of patients benefitted from a test result and
only a small proportion could be used to target therapy
and minimize the use of broad spectrum antibiotics. This
suggests that microbiology laboratory resources could be
spent more efficiently than producing insignificant or nega-
tive results, although negative microbiology test results
may be important for treatment in some infectious disease
patients. Only half of the patients with test results identify-
ing the causative pathogen had their antibiotic treatment
tailored accordingly, meaning that antibiotic treatment was
not optimized for the other half of the patients.
There are several explanations for these findings. Exces-
sive testing and inadequate follow up of test results may
be caused by clinician’s insufficient knowledge of micro-
biology [22, 23]. Diagnostic uncertainty and inadequate
Table 4 Yield of microbiological specimen
Diagnosis* Test findings Blood culture % Urine culture % SST culture1% Respiratory culture % RP-PCR2 % UPAg3 %
Sepsis Causative 20 36 63 29 18 8
Non-causative 5 16 25 58
Negative 75 48 13 13 82 92
Total 100 (n = 303) 100 (n = 239) 100 (n = 24) 100 (n = 52) 100 (n = 106) 100 (n = 111)
UTI Causative 17 54 33 0 0 0
Non-causative 4 17 67 80
Negative 79 28 0 20 100 100
Total 100 (n = 113) 100 (n = 179) 100 (n = 3) 100 (n = 15) 100 (n = 27) 100 (n = 21)
SSTI Causative 4 30 70 40 0 0
Non-causative 4 15 23 60
Negative 92 55 7 0 100 100
Total 100 (n = 163) 100 (n = 47) 100 (n = 107) 100 (n = 5) 100 (n = 11) 100 (n = 4)
LRTI Causative 4 16 67 33 17 9
Non-causative 2 20 22 52
Negative 94 63 11 15 83 91
Total 100 (n = 470) 100 (n = 298) 100 (n = 9) 100 (n = 185) 100 (n = 240) 100 (n = 196)
AECOPD Causative 1 17 43 41 8 10
Non-causative 4 16 43 45
Negative 94 67 14 14 92 90
Total 100 (n = 269) 100 (n = 166) 100 (n = 7) 100 (n = 161) 100 (n = 167) 100 (n = 123)
Total Causative 8 29 67 34 13 8
Non-causative 4 18 25 51
Negative 88 53 8 14 87 92
Total 100 (n = 1318) 100 (n = 929) 100 (n = 150) 100 n = (418) 100 (n = 551) 100 (n = 455)
*AECOPD: acute exacerbation of chronic obstructive pulmonary disease; LRTI: lower respiratory infection; SSTI: skin and soft tissue infection; UTI: urinary tract infection
1SST culture: wound, pus, breastmilk or tissue culture; 2RP-PCR: Respiratory panel polymerase chain reaction test for viral and bacterial respiratory pathogens;
3UPAg: Urinary pneumococcal antigen tests
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routines for microbiology testing in the emergency depart-
ments may also contribute to the large number of un-
necessary test orders [24]. However, the inherent
characteristics of the microbiology tests play a major role
for the yield; although adhering to the guidelines when
sampling specimens, the yield for several tests was low.
However, in this study, we did not have information on
the quality of sampling and transportation of specimens,
which may also impact the yield [8, 25]. Long TATs associ-
ated with certain tests may reduce their utility. We ob-
served particularly long TAT for respiratory cultures. This
may partly be explained by the time-consuming challenge
of identifying and separating respiratory pathogens from
normal bacterial flora. One reason for the continuation of
these practices, both in the microbiology laboratories and
in the clinical units, may be a lack of communication be-
tween the two parties to improve microbiology testing
practices [23].
Our findings show the need for a systematic review of
the use of microbiology tests in clinical practice. Firstly,
tests with low yield should be evaluated, particularly
tests for respiratory infections as our and other studies
show that microbiology test results are of little help to
identify causative pathogens [14, 20, 21]. Thus, more
specific and sensitive tests in the diagnostic work up of
respiratory infections are needed. Secondly, there is a
need to review the indications for microbiology tests.
Obviously, restricting urine cultures to patients with
possible UTIs may reduce unnecessary antibiotic treat-
ment of asymptomatic bacteriuria [26]. Additionally, al-
though the overall yield for blood cultures was low in
our study, it varied significantly between patients
suffering from respiratory infections in the lower end
and sepsis patients in the higher end. This indicates that
a stratification, prioritizing blood cultures for the more
severely ill patients, may be appropriate and increase
overall yield.
Thirdly, there is a need to reduce TATs and increase
the proportion of microbiology test results available at
an early stage of patient treatment. Potential measures
are expansion of molecular diagnostics, rapid and
point-of-care test services, as well as revision of testing
processes within the microbiology laboratories, shown to
reduce TAT significantly [27, 28]. These measures, pro-
moting rapid delivery of microbiology test results with
better performance characteristics, are even more im-
portant in settings with higher rates of AMR than
Norway [29]; In such settings, the identification of
causative pathogens and their susceptibility to antibiotic
agents, is crucial for appropriate and targeted antibiotic
treatment. Furthermore, clinicians need to increase their
knowledge of different microbiology tests; when to order
them and how to apply the test results. Systematic mea-
sures such as providing education, audit with feedback
on microbiology test ordering and use of test results, as
well as establishing decision support for microbiology
testing in computerized provider order entry systems,
may be useful [30]. In order to accommodate all these
challenges adequately, there is a need for clinical- and
microbiology laboratory staff to work in partnership.
Moreover, to develop sustainable and efficient solutions,
there is a need for a targeted and overarching approach.
An improved utilisation of microbiology services is
vital both for the individual infectious disease patients in
Fig. 1 Patient admissions and use of microbiology test results
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need of optimised antibiotic therapy and for the contain-
ment of AMR. Microbiology tests can contribute to re-
duced use of broad spectrum antibiotics and antibiotics in
general, thereby limiting the impetus for development and
selection of drug resistant bacteria. With improved avail-
ability of microbiology test results and increased test accur-
acy, treatment can be more targeted and broad spectrum
antibiotics saved [31]. Additionally, rapid access to micro-
biology test results differentiating viral and bacterial infec-
tions, may reduce unnecessary use of antibiotics [32].
In summary, this study raises several questions regard-
ing the future of microbiology testing. How can we utilize
microbiology testing and the laboratory resources more
efficiently? Which diagnostic tests do we need to develop?
And how can we improve interdisciplinary collaboration
around the infectious disease patient? Thus, more re-
search is needed on how to optimize the collection of
microbiology samples, how to develop and implement
new diagnostic methods and how to reduce TAT for
microbiology tests, taking into account the potential im-
pact on patient outcomes, antibiotic prescribing and de-
velopment of AMR, as well as on use of human and
laboratory resources.
The study has some limitations. Microbiology test results
were mainly based on traditional culturing and Maldi-Tof
MS. Use of novel technology such as molecular diagnostics
could have decreased TAT and increased the proportion of
test results used to inform antibiotic treatment [27]. Patient
data used for analysis in this study were originally collected
for an interventional study on antibiotic prescribing in hos-
pitals [18]. However, we supplemented with microbiology
data to accommodate the needs of this study. Data collec-
tion was limited to departments of internal medicine in
Western Norway, potentially reducing the external validity.
This is however a relatively large, multicentre study, apply-
ing an extensive amount of different data and covering a
wide range of clinical scenarios.
Conclusion
This study identified high compliance with microbiol-
ogy testing recommendations in the national guide-
line. There was however extensive ordering of
additional tests, many tests had low yield and only a
small proportion of test results informed antibiotic
decision-making. This highlights that the current use
of microbiology laboratory services is suboptimal.
There is a need both for tests with better performance
characteristics and improved test ordering practices.
Furthermore, use of microbiology test results to in-
form antibiotic decision-making needs to be optimized
in order to ensure adequate patient treatment and
more targeted therapy. To fill these gaps there is a
need for an overarching approach with a clear call to
fulfil the objective of microbiology testing; to provide
rapid, sensitive test results to individual patients, but
also to facilitate prudent use of antibiotics.
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Interview guide study 1 
The aim of this project is to study hospital doctors` prescribing of antibiotics. We 
want to explore what influences physicians when prescribing antibiotics, to develop 
appropriate measures to improve their prescribing practices. 
 Did you have time to read the information letter? 
Then you are aware that this interview will be taped, transferred from tape to writing, 
and analysed by a team of scientists. The recordings will be deleted by the end of 
2014. We guarantee your confidentiality and you may withdraw from the study at any 
time before the data are published. 
 Do you have any questions so far? 
 Can you please sign the consent form? 
Thank you so much for participating. 
 Can you please tell me how you were recruited to the project? 
 Can you tell me about your backgrounds?  
By background I mean your age, clinical specialty, working position, 
responsibilities, which hospital(s) you have worked at and which university 
you attended.  
Culture 
Do you remember the last time you were on call and a patient was admitted with an 
infection? 
 Can you please describe how you went about to diagnose the patient and 
initiate treatment the patient, what did you do? 
 How did you apply diagnostic tools? 
 
 
Let`s say the patient suffered from a bacterial infection originating from… 
 How did you decide on antibiotic treatment? 
After two or three days you meet the same patient on the ward, and he or she is still 
on the treatment you prescribed. 
 What do you have in mind at this point? 
 What would make you change the antibiotic treatment? 
 In what way does CRP influence your next move? 
 What role do microbiology test results play at this point? 
 How is it to find relevant information in the medical records on what 
considerations have been made regarding the prescribed treatment? 
 When it comes to prescribing of antibiotics, could you please tell me, when do 
you find it difficult to prescribe antibiotics? 
 What do you do when that happens? 
 What role do other doctors, both from your department, but also from other 
departments, play with regard to how you prescribe antibiotics? 
 Nurses, what role do they play with regard to how you prescribe antibiotics? 
Patient characteristics 
 Do you think that the patient and the patient´s condition influence your 
prescribing, and if so, in what way? 
Emotions 
 Can you please describe a situation where there was a discrepancy between the 
antibiotic you should have prescribed and the one you actually prescribed? 




 How is the training on antibiotic prescribing at your department? 
 What emphasis is there on antibiotics in the educational program at this 
hospital? 
 What or who have taught you what you know about antibiotics?  
 How has increasing clinical experience influenced your antibiotic prescribing 
practices? 
 What do you think of antibiotic guidelines? 
Technology 
 What role do electronic tools play when you prescribe antibiotics? 
For instance, do you use the internet, apps or the like? 
 Are there any electronic tools you miss when prescribing antibiotics? 
Structure 
 Is there anything about the way your hospital is organised that could facilitate 
improved prescribing of antibiotics?  
With organisation, I mean schedules, time, staff, medical records, charts and 
so on. 
 How is your access to information and help when you need it? 
 How is the process of retrieving microbiology test results? 
 What do you find beneficial with how the hospital or your department is 
organised, with regards to the prescribing of antibiotics? 
Politics 
 Is your leader concerned about the use of antibiotics, and if yes, in what way? 
 What are your thoughts on antimicrobial resistance? 
 
 
Characteristics of hospitals 
 Can you please tell me how prescribing of antibiotics was done at any other 
hospital you`ve worked at? 
 Why do you think prescribing practices differ between the hospitals? 
Closing remarks  
Finally; if you were to have an unlimited amount of resources available, and should 
give us some advice 
 What measures do you think would be most useful in order to improve 
antibiotic prescribing practices? 
 Is there anything else you would like to add before we finish? 




Interview guide study 2  
Introduction 
We are doctoral- and masters students conducting research on communication 
between microbiology laboratories and clinical hospital units. You probably 
communicate with primary care as well, but that is beyond the scope of this project. 
We aim to get insights into how you perceive the communication with clinical 
hospital units and potential measures for improvement. 
 Did you have time to read the information letter? 
Then you are aware that this interview will be taped, transferred from tape to writing, 
and analysed by a team of scientists. The recordings will be deleted by the end of 
2016. We guarantee your confidentiality and you can withdraw from the study any 
time, before the data are published. 
 Do you have any questions so far? 
 May I ask you to sign the consent form? 
Thank you so much for participating. 
 Can you please tell me how you were recruited to this project? 
 Can you tell me about your backgrounds?  
By background, I mean your age, working position and responsibilities, your 
former workplace(s) and where you were educated. 
 Can you describe a normal day at work? 
 How long are your working hours and on call hours at the laboratory?   
Diagnostic pathway 




«Diagnostic pathway» means the process from e.g. a urinary culture is obtained at the 
clinical unit, the culture is submitted to the laboratory, processed in the laboratory 
and test results are reported back to the health care personnel who ordered the test. 
 Can you tell me how the laboratory is organised according to the diagnostic 
pathway?  
 Can you tell what contributes to optimise the diagnostic pathway?  
 How do you prioritise specimens when processing them?   
 What do you do when you are dealing with a specimen you do not know how 
to process? 
Role 
Now we will discuss the laboratory per se. 
 What, in your opinion, characterises a high quality microbiology laboratory? 
 How would you describe the laboratory´s role in the hospital?  
(In relation to patients, clinicians, clinical units etc.) 
 What is your role in this context? 
Education/experience 
Now we will talk about education and experience.  
 Can you tell me what insights you got during your training about the patient 
and how your profession can contribute to the patient treatment? 
 In your current position, what or who has taught you the most about what 
microbiology tests mean for patients and patient treatment?  
 Can you give me any examples? 
 At this workplace, what opportunities do you have for education and 
development of competencies?   
 
 
Communication with clinical units 
Moving on to communication between the laboratory and clinical hospital units;  
 Can you describe how the laboratory communicates and collaborates with the 
clinical units at the hospital? 
 Alternatively, when you communicate with the clinical hospital units? 
 Who is available at any time at the laboratory to answer questions from the 
clinical units?  
 Can you describe situations where you thought that communication with 
clinical units went really well? 
 Can you describe situations where communication with clinical units went 
really bad? 
 Who in the clinical units do you mainly communicate with? 
 Can you estimate how much time you spend on communicating with clinical 
units per day?  
 What do you find most challenging when communicating with the clinical 
units? 
 What role do IT-systems play for the communication between the laboratory 
and the clinical units? 
 Can you describe the importance of other factors that are important for the 
communication between the laboratory and clinical units? 
Meaning e.g. specimen and test result logistics, organisation within the 
laboratory, meetings with clinical staff, opening hours, economy, laws and so 
on. 
 Can you describe how the laboratory, and potentially you, communicate with 





Now we will talk about leadership;  
 According to the Head of the laboratory, what is considered the laboratory´s 
most important task? 
 What has he or she said about communication with the clinical units? 
 What are your manager´s responsibilities at the laboratory? 
 What is your manager´s primary concern at the laboratory? 
 Are there any other members of the staff that influence the laboratory´s 
priority settings? 
Improvements 
Now we are to move on to the last part of this interview;  
 Do you have any suggestions as to how to improve the communication 
between the laboratories and the clinical units? 
 What would improve the communication for you? 
 What do you think would improve communication for the clinical units?  
Closing remarks 
If I am to summarise your statements, I would say that… 
 Do you find the summary appropriate? 
 Do you want to add anything?  
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